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ABSTRACT 
 
Streptococcus pneumoniae is a global cause of disease including pneumonia, 
otitis media, conjunctivitis, sepsis, and bacterial meningitis. These infections are 
not essential to the transmission or long-term survival of the bacterium; indeed, 
S. pneumoniae depends on asymptomatic colonization of the human 
nasopharynx for its dissemination to additional hosts. Considering this, 
colonization studies are a good way to monitor changes in the pneumococcal 
epidemiology that may result from the use of antibiotics and vaccines. The 
molecular characterization of pneumococci is crucial to assess these changes 
which highlight the need for the development and validation of easier and faster 
methods of molecular typing. 
 
Since 1996 our group has been monitoring the pneumococcal population 
colonizing children attending day care centers. However, for several years these 
studies have been confined to the Lisbon area. In this PhD we have addressed 
this situation by including other regions of Portugal in our study. In addition, we 
have started to study pneumococcal colonization in the elderly, the other age 
group where the incidence of pneumococcal infections is high.  
 
This thesis summarizes five studies conducted during this PhD. The first four 
studies were focused on the pneumococcal epidemiology among the two age 
groups where the rates of pneumococcal disease are highest: children up to six 
years old and adults older than 60 years. The fifth and last study describes the 
evaluation and validation of a new genotyping strategy for pneumococci. 
 
The first study was a retrospective study aimed to describe the epidemiology of 
the recently discovered serotype 6C colonizing healthy children attending day 
care centers between 1996 and 2007. In that study, using PCR serotyping and 
the Quellung reaction, pulsed-field gel electrophoresis (PFGE), multilocus 
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sequence typing (MLST), and antibiotyping, we observed that this serotype had 
been circulating in Portugal since at least 1996, it is genetically diverse, and 
often antibiotic resistant.  
 
The second study was conducted in Coimbra and aimed to determine the 
prevalence of pneumococcal carriage and to characterize the pneumococcal 
strains colonizing children attending day care centers in this region in the era of 
pneumococcal vaccines. Between January and February 2007, nasopharyngeal 
swabs were obtained from 507 children (76.7% had received at least one dose 
of PCV7) and 61.3% were pneumococcal carriers. All 311 pneumococcal 
samples were antibiotyped and serotyped and the pneumococcal strains that 
were resistant to at least one antibiotic were also typed by PFGE. We have 
found in Coimbra similar rates of colonization and antimicrobial resistance 
patterns and similar genotypes to those previously described in the Lisbon area.  
 
The aim of the third study was to compare the patterns of colonization among 
young children who attended day care centers and lived in two different areas: 
an urban area, Oeiras, and Montemor-o-Novo, a rural area in the Southern part 
of Portugal. In this study 1088 and 756 nasopharyngeal swabs from day care 
center attendees from urban and rural area, respectively, were collected. 
Pneumococcal strains were characterized by antibiotype and serotype. Similar 
rates of colonization (c.a. 61%) were found; however, in the urban area there 
were higher rates of antimicrobial resistance (32.4% vs 21.6%, p<0.001) and 
higher rates of antimicrobial consumption one month before sampling (16.7% vs 
11.6%, p=0.004). Multivariable logistic regression analysis was performed to 
identify the factors associated with differences between the two regions. 
Antibiotic consumption during last month, being colonized with serotype 19A or 
non-typeable strains, and attending day care in Oeiras and being colonized with 
serotype 19A, were risk factors for being colonized by pneumococcal resistant 
strains. This study highlighted that in the era of widespread use of 
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pneumococcal conjugate vaccines in Portugal, antibiotic consumption remains a 
main driving force for the maintenance of antimicrobial resistant pneumococci in 
the community. 
 
To gain insights into the pneumococcal carriage patterns among the elderly, the 
fourth study was performed in two distinct areas: Oeiras and Montemor-o-Novo. 
In this study, 1,298 nasopharyngeal samples were collected. All pneumococci 
were antibiotyped, serotyped and characterized by MLST. Association between 
pneumococcal carriage, socio-demographic and clinical factors was evaluated 
using a logistic regression. The rates of colonization in this age group were low 
(2.2%), but there were high variability of colonizing serotypes and genetic 
backgrounds. Out of the 30 pneumococcal isolated, sixteen showed 
antimicrobial resistance. Smoking was a risk factor for pneumococcal 
colonization and living in the rural area seemed to increase the rate of 
pneumococcal colonization in this population. This study provided an important 
baseline to monitor the impact of pneumococcal vaccines on the patterns of 
colonization among the elderly. 
 
In the last part of this thesis, we described and validated a newly developed 
multiple-locus variable tandem repeat analysis (MLVA) method to easily and 
rapidly genotype pneumococcus. This method was compared to the current gold 
standards methods, MLST and PFGE. The three typing methods showed 
Simpson´s diversity indices of 98.5% or higher. The Wallace coefficient of MLVA 
and MLST was 0.874, meaning that if two strains had the same MLVA type they 
had an 88% chance of having the same MLST type. For some isolates 
belonging to a single MLST clonal complex, despite displaying different 
serotypes, MLVA was more discriminatory, generating groups according to 
serotype or serogroup. This study showed that MLVA is a promising genotyping 
method for S. pneumoniae. 
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Altogether, these studies have contributed to improve our knowledge on 
pneumococcal colonization in Portugal in two age groups, children and the 
elderly.  
 
The main conclusions of this thesis were: 
 
i) the recently described serotype 6C is frequently carried by healthy young 
children in Portugal, is genetically diverse, and has been circulating in 
our country at least since 1996; 
ii) the patterns of pneumococcal colonization among healthy children living 
in Coimbra are similar to those living in the Lisbon area; 
iii) antibiotic consumption remains a main cause for the maintenance of 
antimicrobial resistance, in the era of widespread use of pneumococcal 
conjugate vaccines;  
iv) the rates of pneumococcal colonization in the elderly are low and the 
serotype and genotype diversity are high; 
v) MLVA is a promising genotyping method to characterize pneumococci.  
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RESUMO 
 
Streptococcus pneumoniae, ou pneumococos, é responsável por várias 
doenças em todo o mundo nas quais se incluem as infeções do trato 
respiratório, do ouvido médio, conjuntivite, meningite e sepsis. No entanto, é a 
elevada prevalência na nasogaringe em portadores assintomáticos que 
contribui para a sua disseminação na população. Assim, os estudos de 
colonização por pneumococos são importantes pois permitem monitorizar a 
flora da nasofaringe em vários grupos etários, e estudar a influência da 
utilização de vacinas e do uso de antibióticos. Igualmente importante é a 
possibilidade de otimização das vacinas de acordo com as características da 
população alvo. A caracterização molecular de pneumococos é crucial para a 
avaliação dessas alterações, o que alerta para a necessidade do 
desenvolvimento e validação de métodos de tipagem molecular fáceis e 
rápidos.  
 
Desde 1996 que o nosso grupo tem vindo a estudar a população pneumocócica 
em crianças saudáveis que frequentam creches e jardins de infância. No 
entanto, esses estudos estiveram desde sempre confinados à área da grande 
Lisboa. Com o intuito de obter uma amostra populacional mais abrangente e 
variada, esta tese inclui estudos de outras regiões de Portugal não só em 
crianças mas também na população idosa, uma vez que este último constitui 
também um grupo etário de risco, com elevada incidência de doença 
pneumocócica.  
 
Nesta tese são apresentados cinco estudos que foram realizados durante este 
doutoramento. Os primeiros quatro estudos focaram-se na epidemiologia de 
pneumococos, tendo sido envolvidas nos primeiros três, crianças até aos 6 
anos de idade e no quarto estudo, adultos com mais de 60 anos. O quinto e 
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último estudo descreve e faz-se a validação de uma nova estratégia de tipagem 
molecular para pneumococos. 
O primeiro trabalho é um estudo retrospectivo que descreve a epidemiologia de 
um serotipo recentemente descoberto, 6C. Este estudo utilizou amostras que 
foram recolhidas da nasofaringe de crianças saudáveis que frequentavam 
creches e jardins de infância entre 1996 e 2007. Nesse estudo, utilizou-se a 
serotipagem por PCR complementada com a reacção de Quellung, 
electroforese em campo pulsado (PFGE), “multilocus sequence typing” (MLST) 
e antibiograma, para caracterizar os isolados. Concluiu-se que este serotipo já 
circulava em Portugal pelo menos desde 1996, que é geneticamente diverso, e 
que frequentemente apresenta resistência a antibióticos.  
 
O segundo estudo foi realizado em Coimbra e teve como objectivos determinar 
a prevalência de portadores de pneumococos e caracterizar as estirpes de 
pneumococos que colonizam crianças que frequentam creches e jardins de 
infância nesta região, na era das vacinas pneumocócicas. Entre Janeiro e 
Fevereiro de 2007 foram pesquisadas 507 crianças (76.7% tinham recebido 
pelo menos uma dose de vacina pneumocócica conjugada 7-valente) das quais 
61.3% eram portadores de pneumococos. Todos os 311 pneumococos isolados 
foram serotipados e foi realizado o antibiograma. Às estirpes de pneumococcus 
que apresentavam resistência a pelo menos um agente antimicrobiano foi 
também realizada a tipagem por PFGE. Em Coimbra as taxas de colonização, 
os padrões de resistência a antibióticos e os genotipos encontrados foram 
semelhantes aos descritos previamente na área metropolitana de Lisboa.  
 
O objectivo do terceiro estudo foi comparar os padrões de colonização em 
crianças que vivem e frequentam creches e jardins de infância em duas áreas 
distintas: uma área urbana, Oeiras, e uma área rural na região centro-sul de 
Portugal, Montemor-o-Novo. Neste estudo foram recolhidas 1088 e 756 
zaragatoas da nasofaringe de crianças da área urbana e da área rural, 
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respectivamente. Os pneumococos foram caracterizados por serotipagem e 
antibiograma. As taxas de colonização encontradas foram semelhantes nas 
duas regiões (c.a. 61%). No entanto, na área urbana o nível de resistência a 
agentes antimicrobianos foi mais elevado (32.4% vs 21.6%, p<0.001), o mesmo 
acontecendo relativamente às taxas de consumo de antibióticos um mês antes 
da amostragem (16.7% vs 11.6%, p=0.004). Foi realizada uma análise 
estatística multivariada para identificar os fatores associados às diferenças 
encontradas nas duas regiões. O consumo de antibióticos durante o mês 
antecedente à recolha da amostra, estar colonizado com o serotipo 19A ou com 
uma estirpe não-tipável, e frequentar creche ou jardim de infância em Oeiras 
foram considerados fatores de risco para a colonização por pneumococos 
resistentes a antibióticos. Este estudo alerta para o facto do consumo de 
antibióticos continuar a ser a principal causa para a manutenção dos níveis de 
pneumococos resistentes a antibióticos encontrados na comunidade apesar da 
grande utilização de vacinas pneumocócicas conjugadas na comunidade infantil 
em Portugal.  
 
O quarto estudo foi realizado com o objetivo de obter informação relativa aos 
padrões de colonização de pneumococos na população idosa. Neste estudo, 
1298 amostras da nasofaringe foram recolhidas em duas áreas distintas: Oeiras 
e Montemor-o-Novo. Todos os pneumococos foram serotipados e 
caracterizados por MLST e foi também realizado o antibiograma. A associação 
entre portadores de pneumococos, fatores socio-demográficos e fatores 
clínicos foi avaliada usando uma regressão logística. As taxas de colonização 
neste grupo etário foram baixas (2.2%), mas encontrou-se uma grande 
variedade de serotipos e genotipos. Dos 30 pneumococos isolados, 16 
mostraram resistência a agentes antimicrobianos. Foram identificados como 
fatores de risco para a colonização por pneumococos tabagismo e habitar em 
área rural. Este estudo possibilitou a criação de uma importante linha de 
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referência para monitorizar o impacto das vacinas pneumocócicas nos padrões 
de colonização nos idosos.  
 
Na última parte desta tese foi descrita e validada uma nova estratégia de 
“multiple-locus variable tandem repeat analysis” (MLVA) aplicada a 
pneumococos que permite de uma forma fácil e rápida, fazer uma análise 
genotípica deste microrganismo. Este método foi comparado com os métodos 
mais utilizados atualmente MLST e PFGE. Os três métodos mostraram índices 
de diversidade de Simpson de 98.5% ou superiores. O coeficiente de Wallace 
para MLVA e MLST foi de 0.874, o que significa que se duas estirpes tiverem o 
mesmo tipo de MLVA tem 88% de probabilidade de terem o mesmo tipo de 
MLST. O MLVA foi mais discriminativo para alguns isolados do mesmo 
complexo clonal (por MLST), gerando grupos de acordo com o serotipo ou 
serogrupo. Este estudo mostrou que o MLVA é um método promissor para 
genotipar S. pneumoniae. 
 
Em suma, os trabalhos apresentados contribuíram para melhorar o nosso 
conhecimento em relação à colonização por pneumococos em Portugal em 
duas faixas etárias, crianças e idosos. As principais conclusões desta tese 
foram:  
 
i) o serotipo 6C, recentemente descrito, é frequentemente encontrado em 
crianças saudáveis em Portugal, é geneticamente diverso e tem estado 
em circulação no nosso país pelo menos desde 1996; 
ii) os padrões de colonização por pneumococos em crianças saudáveis 
que vivem em Coimbra são semelhantes aos encontrados nas crianças 
que vivem na área de Lisboa; 
iii) o consumo de antibióticos continua a ser a principal causa da 
manutenção da resistência antimicrobiana na era da grande utilização 
de vacinas pneumocócicas conjugadas;  
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iv) as taxas de colonização por pneumococos nos idosos são baixas mas a 
diversidade de serotipos e de genotipos é elevada; 
v) o MLVA é um método de genotipagem promissor para caracterizar 
pneumococos.  
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THESIS OUTLINE 
 
The studies presented in this thesis provide an overview of pneumococcal 
colonization in Portugal in two age groups: children and the elderly. 
 
Chapter I provides an outline of Streptococcus pneumoniae as a bacterium that 
frequently colonizes the nasopharynx but can be also responsible for serious 
diseases. Topics such as historical highlights, epidemiology, identification, 
typing methods and the effect of pneumococcal vaccines are addressed. 
 
Chapter II describes the temporal trends and molecular epidemiology of the 
recently described serotype 6C of Streptococcus pneumoniae. The study 
analyses the evolution of this serotype from 1996 to 2007, by antibiotyping, 
serotyping and also using PFGE and MLST. 
 
Chapter III describes the pneumococcal population colonizing the nasopharynx 
of children attending day care centers in Coimbra, a city in the central region of 
Portugal.  
 
Chapter IV compares the patterns of pneumococcal colonization of young 
children attending day care centers in two distinct areas of Portugal: one rural, 
Montemor-o-Novo, and other urban, Oeiras. 
 
Chapter V is a study of pneumococcal colonization in the elderly in Portugal 
that was also performed in an urban area, Oeiras, and a rural area, Montemor-
o-Novo. 
 
Chapter VI describes and validates a novel genotyping strategy applied to 
pneumococci: multiple-locus variable tandem repeat analysis (MLVA).  
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Chapter VII presents general conclusions and futures perspectives. 
 
Chapters II to VI are reproductions of the publications indicated below. They 
can be read independently. 
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General Introduction 
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INTRODUCTION 
 
Streptococcus pneumoniae, or pneumococcus, is a Gram-positive bacterium 
responsible for high rates of mortality and morbidity worldwide. It is a leading 
cause of disease particularly among young children, the elderly, and the immuno-
compromised of all ages. Although it colonizes asymptomatically the nasopharynx, 
S. pneumoniae can cause otitis media, sinusitis, pneumonia and more severe 
diseases such as bacteremia and meningitis. Pneumococcal disease remains a 
great concern worldwide despite great advances aiming to decrease it, such as 
the use of antibiotic therapy and prevention through vaccination.  
 
Since colonization precedes disease, epidemiological studies monitoring the 
nasopharynx flora are valuable tools to anticipate the emergence of serotypes that 
may became responsible for disease in the future.  
 
 
HISTORICAL HIGHLIGHTS 
 
In 1875 Edwin Klebs was the first to recognize Streptococcus pneumoniae in lung 
tissue and in infected sputum (reviewed in (54)), but only six years later this 
bacterium was isolated by two researchers working in France and the USA. In 
January 1881, Louis Pasteur in France reported for the first time the isolation of S. 
pneumoniae, after finding bacteria in the saliva of a youngster with rabies. George 
Miller Sternberg was in New Orleans studying malaria fever when he sampled his 
own saliva (as a control for his experiments) and injected it subcutaneously in a 
rabbit, which quickly died. This observation was in September 1880, but did not 
publish his report until April 1881(reviewed in (54)). 
 
More than 90 years went by before this bacterium was named as Streptococcus 
pneumoniae. Pasteur called his isolate the “microbe septicémique du saliva” and 
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Sternberg called his “Micrococcus pasteuri”. In 1883 Mátray applied the term 
“pneumoniekokken” and Albert Fraenkel in 1886, after the first complete 
description of the bacterium, gave us the familiar name “pneumokokkus”. In the 
same year, Anton Weichselbaum suggested the name Diplococcus pneumoniae, 
which was used until the reclassification, on the basis of its growth in chains in 
liquid medium, as Streptococcus pneumoniae, in 1974 (reviewed in (54)). 
 
After its isolation and identification, S. pneumoniae was the model organism used 
in important discoveries, including Gram staining in 1884 and the putative use of 
polysaccharide antigens as vaccines (reviewed in (54)). The identification of DNA 
as the source of genetic information was done using pneumococcus. Griffith in 
1928 showed that avirulent strains could be transformed into virulent strains. 
Avery, MacLeod and McCarty demonstrated in 1944 that DNA was responsible for 
the transformation and thus the carrier of genetic information (reviewed in (54)). 
The therapeutic efficacy of penicillin, the role of bacterial capsule in resistance to 
phagocytosis (reviewed in (54)), and the first quorum sensing factor (149) were 
also described for the first time in pneumococci. 
 
 
EPIDEMIOLOGY OF PNEUMOCOCCI 
 
Diseases caused by the pneumococcus constitute a major global public health 
problem. According to the World Health Organization (WHO), in 2005, about 1.6 
million deaths were caused by this agent annually, from which 0.7-1 million were 
among children under five years. In developing countries, pneumococcal disease 
is common in children under two years; in the elderly population the burden of 
disease is largely unknown. HIV infection and other conditions associated with 
immunodeficiency greatly increase the likelihood of contracting pneumococcal 
disease. Of the deaths occurring in HIV-negative children, over 60% occur in ten 
African and Asian countries (109) (Figure 1).  
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In the USA and Europe S. pneumoniae is the most common cause of pneumonia 
in adults. The annual incidence of invasive pneumococcal disease (IPD) in these 
regions ranges from 10 to 100 cases per 100,000 (WHO, 
www.who.int/ith/disease/pneumococcal). 
 
 
 
Figure 1. – Rates of Streptococcus pneumoniae death (per 100,000 children under age 5). 
Data from WHO August, 2009.  
 
Pneumococcal carriage 
The pneumococcus is a normal component of the nasopharyngeal mucous 
membrane microflora. Acquisition is the first stage towards carriage and possible 
infection with pneumococcus. Carriage is usually asymptomatic. Transmission 
occurs by airborne droplets or direct contact with respiratory secretions (102). 
Recently, it has been suggested that environmental surfaces may also serve as 
sources of pneumococcal infection as pneumococci were found to be able to 
survive long-term desiccation (157).  
 
G
e
n
e
ra
l in
tro
du
ct
io
n
 
6 
 
Children are the major carriers and colonization occurs soon after birth (6). The 
peak in incidence is more or less at three years of age (15) and then declines with 
increasing age, until 10 years of age, remaining low in adulthood (15). Few studies 
have studied nasopharyngeal colonization in the elderly, but the carriage rates are 
typically low, ranging between 2 and 5% (2, 15, 68, 121).  
 
Since it is in young children where the highest frequency of pneumococcal 
colonization and the highest crowding index are found, this group is considered 
the most important vector for horizontal dissemination of pneumococci in the 
community (88). Consequently, part of the strategy to prevent pneumococcal 
disease focuses on prevention of nasopharyngeal colonization. 
 
In Portugal, data of pneumococcal carriage in healthy children attending day care 
centers, have been published by our group since 1996 and rates have been 
generally close to 60-65% (42, 43, 95, 104, 125, 128, 137). Concerning 
colonization in the elderly in Portugal, no studies had been conducted until 
recently. This topic was addressed for the first time in the pioneer study described 
in Chapter V of this thesis. 
 
Pneumococcal carriage is not a permanent state. In fact, once established in the 
nasopharynx, pneumococci are cleared within weeks to months; subsequently the 
nasopharynx can be recolonized by another strain. The duration of carriage is 
variable (5 to 290 days) depending on the serotype and the age of the carrier (53, 
141, 143). Risk factors for colonization among others are young age (lower than 6 
yrs), having young siblings, crowding (e.g. attending day-care centers, prisons, 
military training campus, sports with contact, retirement homes), season, low 
socioeconomic status, other respiratory infections such as influenza, 
immunosuppression such as HIV-infection, exposure to cigarette smoke, and 
asthma (1, 7, 23, 51, 53, 80). 
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Most studies on pneumococcal colonization studies are based on the 
characterization of a single isolate of each individual. However, more than one 
pneumococcal serotype or clone can coexist in the nasopharynx of an individual 
(50, 53, 108, 129, 151). For this reason, studies on co-colonization are very 
important to identify changes at the individual level, such as de novo acquisition, 
clearance and unmasking of pneumococcal strains (which can include serotypes 
or clones) (37, 90), particularly in the era of multivalent pneumococcal conjugate 
vaccines.  
 
Pneumococcal disease 
S. pneumoniae may spread from the nasopharynx into the respiratory tract or the 
bloodstream to cause infections. These infections can be divided in two groups: 
invasive (isolated from sterile body sites) and non-invasive (isolated from non-
sterile body sites). Otitis media and sinusitis are non-invasive infections. The 
nasopharynx is connected with the middle ear cavity via the Eustachian tube, 
which is a pressure regulator and prevents the entrance of the bacteria in the 
middle ear cavity. However, if the Eustachian tube is blocked, the bacteria may be 
trapped in the middle ear and cause otitis media. Sinusitis is caused when the 
bacteria spread locally into the sinuses and cause an accumulation of fluids in the 
sinuses due to an obstruction. The pneumococcus can also be responsible for 
more severe infections such as pneumonia, bacteremia and meningitis. From the 
nasopharynx, the bacteria may spread into the lungs or directly to the 
bloodstream. If bacteria spread into the lungs the immune system reacts and the 
accumulation of fluids and bacteria in the alveoli decreases oxygen transport and 
causes pneumonia (74). In adults, pneumonia without bacteremia is the most 
common non-invasive pneumococcal infection, however if the pneumococcus 
spreads into bloodstream, the infection becomes invasive. Pneumonia with 
bacteremia and meningitis are the most frequently recognized invasive disease. 
Pneumococcal meningitis occurs when the bacteria spread directly to bloodstream 
into the meninges (membranes that surround and protect the brain and spinal 
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cord). The meninges are filled with a liquid called cerebrospinal fluid where the 
bacteria can multiply freely, causing inflammation and swelling of the meninges 
and the brain tissue. Other invasive diseases are sepsis, peritonitis and arthritis. 
 
Risk factors for pneumococcal infection are numerous and include, among many 
others, extremes of age (under 5 years of age and over 60 years old), 
immunosuppression, presence of underlying medical conditions, defects in host 
immune responses, low socioeconomic status, malnutrition, cigarette smoking and 
alcoholism (29, 91, 106, 107).  
 
In Portugal, the report of pneumococcal infectious disease is not mandatory and, 
to my knowledge, no study has been carried out to calculate the incidence of 
invasive pneumococcal disease (IPD) over time. However, epidemiological studies 
on pneumococcal infections using data from several hospitals in different areas of 
Portugal have been conducted (3, 5, 63, 134, 135).  
 
 
PROPERTIES OF STREPTOCOCCUS PNEUMONIAE 
 
Streptococcus pneumoniae is a lancet-shaped Gram-positive bacterium, whose 
diameter ranges between 0.5 and 1.25 µm for an individual cell. Pneumococci are 
frequently seen as pairs of cocci (diplococci), but they can also be in single cell 
and in short chains. It is a fastidious organism, growing best in media containing 
blood and in an enriched atmosphere with 5% CO2. On blood agar, colonies 
characteristically produce alpha hemolysis, form an inhibition halo ≥14 mm around 
a 5 mg optochin disc, and are soluble in bile salts (e.g. deoxycholate). Addition of 
a few drops of 10% deoxycholate at 37°C, lyses the entire culture in minutes. The 
majority of pneumococci have a polysaccharide capsule and the assignment of a 
capsule type through serotyping is also used for identification of this bacterium. 
However, some pneumococci do not have a capsule and others give an atypical 
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result in one or more of the assays described above (4, 32, 105, 111, 117, 127, 
138). 
 
The capsule is the main virulence factor of the pneumococcus and, with the 
exception of serotype 3, is covalently linked to the peptidoglycan of the cell wall 
(146). The capsule is 200 to 400nm thick (140), protects against 
opsonophagocytosis, and plays an important role in the interaction between the 
bacteria and the epithelium in colonization of the upper respiratory tract (103, 158). 
In addition, the pneumococcus may shift from transparent-phase (capsule less 
dense and thicker cell wall) to opaque-phase and vice-versa. This allows for 
attachment to the epithelial cells in carriage. The pneumococci in opaque-phase 
have denser capsules, providing better protection against opsonization and killing 
in invasive disease (159). 
 
Based on the reaction of the capsular polysaccharide with polyclonal factor sera 
and more recently with the use of monoclonal antibodies, 94 serotypes are 
recognized up to now (16, 21, 22, 61, 115). 
The first “novel” serotype recognized using monoclonal antibodies was 6C (115). 
As it was previously classified as 6A by the Quellung reaction, the real prevalence 
of this serotype and its characteristics were not known. In order to obtain insights 
on its epidemiology in colonization in Portugal, a retrospective study was 
performed and is described in this thesis in Chapter II.  
 
Distribution of serotypes 
Although 94 distinct pneumococcal serotypes, varying in capsular polysaccharide 
structure, have been described, not all seem to have the same capacity to cause 
disease (18, 60, 126, 136). Some serotypes can be carried in the nasopharynx 
asymptomatically and cause disease in a small proportion of infected individuals 
only. Others are rarely identified in the nasopharynx but are frequently associated 
with disease. Serotypes 1 and 5 are examples of serotypes that rarely are 
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detected in colonization, but are responsible for a high proportion of invasive 
disease and are frequently associated with outbreaks (8, 13, 38, 96, 123). Before 
the introduction of pneumococcal conjugate vaccines 10 to 12 serogroups were 
responsible for the majority of pneumococcal invasive disease worldwide, 
including 1, 3, 4, 6A, 6B, 7F, 8, 9V, 14, 18C, 19F, and 23F (62, 112).  
 
The prevalence of pneumococcal serotypes/serogroups causing IPD depends on 
several factors, such as geographic location, disease manifestation, and age of 
the host (15, 18, 19, 60). In young children the serogroups/serotypes 6, 14, 18, 19 
and 23F are predominant due to the lower immunogenicity of these serotypes 
(20).  
Several authors have been looking at the distribution of serotypes in colonization 
and disease to estimate the invasive potential (18, 19, 55, 131, 141). According to 
Brueggeman et al. (18) and Sleeman et al. (141) serotypes 1, 4, 5, 7F, 9V, 14, 
18C, and 19A are classified as highly invasive serotypes. In a study reported by 
Greenberg et al. (55) the authors estimated the disease potential in pediatric 
community-acquired alveolar pneumonia. In this study the nasopharyngeal 
samples were also taken from healthy children during disease and the serotype-
specific odds ratios were calculated. They observed that serotypes 1, 5, 7F, 9V, 
14, 19A, and 22F have a higher disease potential than serotypes 6A, 6B, 23A, and 
35B in childhood pneumonia. In Israel another study was conducted to assess the 
invasive disease potential of pneumococcal serotypes causing IPD, acute otitis 
media and acute conjunctivitis in children. Odds ratios for each disease were 
calculated and a significant positive association with IPD was found for serotypes 
1, 5 and 12F. Also, a significant positive association was found in otitis media for 
serotypes 1, 3, 5, 12F, 19A and 19F, and in acute conjunctivitis, for serotype 3 and 
NT strains. On the other hand, a significant negative association with IPD was 
found in NT strains and in acute otitis media in serotypes 6A, 6B, 15A and NT 
strains (136).  
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In Portugal, a study was published (126) where the invasive disease potential of 
serotypes and clones circulating in Portugal before the introduction of PCV7 was 
calculated. In this study serotypes 1, 3, 4, 5, 7F, 8, 9N, 9L, 12B, 14, 18C and 20 
were found to have a high propensity to cause invasive disease, whilst serotypes 
6A, 6B, 11A, 15B/C, 16F, 19F, 23F, 34, 35F, and 37 were associated with 
carriage. Additionally, significant differences in invasiveness were found between 
clones that shared the same serotype, namely among serotypes 3, 6A, 6B, 11A, 
14, 19A, 19F, 22F, 23F, 34 and NT, which highlights the importance of the genetic 
background when analyzing the invasive disease potential of certain serotypes. 
The distribution of serotypes is also affected by temporal changes, inherent of 
secular trends of specific serotypes, and this has been reported in several studies 
(57, 59, 71, 120).  
Serotype distribution can be altered by antibiotic consumption and vaccination 
patterns. Following the introduction of the first pneumococcal conjugate vaccine, 
the increase of non-vaccine serotypes has been reported in several countries, in 
disease and also in colonization (more details are presented in the next topic).  
Use of antibiotics and pneumococcal vaccines 
Nowadays, the main tool to control pneumococcal disease, besides antibiotic 
therapy, is vaccination. Efforts to develop effective pneumococcal vaccines began 
in 1911, when the first clinical trial on the effectiveness of a whole-cell 
pneumococcal vaccine was conducted by Wright et al. in South-Africa (reviewed in 
(93)). Several decades were needed before the effectiveness of pneumococcal 
vaccines was demonstrated. Only at the end of World War II in 1945 (92), the first 
capsular polysaccharide vaccine trials were undertaken.  
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Antimicrobial resistance 
Before penicillin became available for medical treatment in the early 1940s, no 
cure for pneumonia existed and many people died with pneumococcal infection. 
The introduction and use of antimicrobial drugs changed this scenario and led to 
the withdrawn from the market of a pneumococcal vaccine that was licensed and 
in usage. However, it did not take long before it became clear that antimicrobials 
per se had not eliminated pneumococcal disease. 
 
In 1964, Austrian and Gold reported that one in four patients admitted with 
pneumococcal bacteremia died even with antimicrobial therapy (12). In 1967, the 
first pneumococcal isolate with intermediate resistance to penicillin was described 
by Hansman et al. (58) in Australia. Within a decade, similar strains were found in 
South Africa, Europe and North America (77). The first multiresistant 
pneumococcal isolates were reported by Jacobs et al. in 1978 (70) and since then 
we have been observing a widespread of multidrug resistance has been observed 
(33, 97).  
The rates of antimicrobial resistance differ from country to country and depend on 
several factors as antibiotic consumption habits, use of pneumococcal vaccines, 
and geographic areas. The last report from the European Antimicrobial Resistance 
Surveillance Network (EARS-Net Database) from 2010 indicated that, in Europe, 
pneumococcal resistance to macrolides ranges between 4%, in Sweden and UK, 
and around 30% in Spain and France. Concerning the prevalence of penicillin non-
susceptible pneumococci, Belgium showed the lower rate (0.4%) and, in contrast, 
Spain and France appear in the top of the ranking, with values of 27.6% and 
29.8%, respectively (45). In the USA, in 2008 CDC reported that 10.7% of the 
pneumococcal isolates in invasive disease showed decreased susceptibility to 
penicillin. Resistance to macrolides increased in all parts of the USA since 2000 
and in 2006 the rate was 30% (72). In Asian countries in non-meningeal isolates 
recovered from 2008-2009, 5.3% of the isolates showed a MIC≥4 µg/mL to 
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penicillin. Resistance to erythromycin was very prevalent, 72.7%, and multidrug 
resistance was observed in 59.3% of the isolates (76) (reviewed in (144)). 
 
In Portugal, among invasive disease isolates in adults, the latest data (2006-2008) 
showed rates of penicillin non-susceptibility around 17% and the resistance to 
macrolides was 18% (63). In children (including children until 17 years) during the 
same period, around 19% of the isolates expressed non-susceptibility to penicillin 
and resistance to erythromycin was found in 22.9% of the isolates. Additionally 
11.6% of the isolates showed simultaneously resistance to both antimicrobial 
agents. In young healthy children data from 2006/2007 showed rates of 
macrolides resistance of 25.3% and 26.6% of the strains showed decreased 
susceptibility to penicillin (137).  
 
Pneumococcal vaccines 
In 1977, Austrian et al. reinforced the interest of pneumococcal prevention and a 
pneumococcal polysaccharide vaccine including 14 serotypes was licensed (11). 
This vaccine was extended to 23 serotypes and licensed in 1983 (Pneumovax23, 
Merck&Co, PPV23).  
 
In children, responses induced by polysaccharide vaccines are low (44). 
Conjugation of the polysaccharides with a carrier protein induced better antibody 
responses in infants due to the T-cell dependent immune pathway. In 2000, the 
first pneumococcal conjugate vaccine was licensed (Prevnar™; Wyeth-Lederle, 
PCV7). It included the seven serotypes most common in pneumococcal disease in 
children under 2 years old in the United States (4, 6B, 9V, 14, 18C, 19F and 23F). 
In PCV7 the polysaccharide of each serotype is individually conjugated to the 
protein carrier, CRM197. In Portugal, this vaccine was neither introduced in the 
National Vaccination Plan nor subsidized by the state. However, the majority of 
pediatricians recommended this vaccine what explained high intake of the vaccine; 
the most frequently used was three doses at 2, 4, 6 months and a booster after 12 
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months. Data obtained from Pfizer, Portugal, and our data from colonization 
studies in the Lisbon area, until 2007 (137), around 70% of the children under six 
years old were vaccinated suggested that at least one vaccine dose. 
In 2009, a new pneumococcal conjugate vaccine was introduced in the market 
(Synflorix®, GlaxoSmithKline Inc., PCV10). It included the same serotypes in 
PCV7 plus three additional serotypes (1, 5, 7F; serotypes 18C and 19F are 
conjugated to tetanus and diphtheria toxoids, respectively, and the remaining 8 
serotypes are conjugated to the non-typeable Haemophilus influenzae protein D).  
 
In 2010, PCV7 was replaced by PCV13 (Prevenar®; Pfizer). This vaccine included 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. These vaccines 
have not been introduced in the National Vaccination Plan, and are not subsidized 
by the state in Portugal. 
 
According to the Global Alliance for Vaccines and Immunisation (GAVI), in July of 
2012, 18 countries in the developing world started the introduction of 
pneumococcal conjugate vaccine and 36 GAVI eligible countries have been 
approved for GAVI support to introduce pneumococcal conjugate vaccine into the 
national immunization programmes. GAVI and partners hope that by 2015, 90 
million children can be immunized with pneumococcal vaccines and the 
pneumococcal vaccine rollout has been achieved in 58 countries 
(http://www.gavialliance.org). 
 
Recent data from Active Bacterial Core Surveillance (ABCs) in the USA indicated 
a decreased in the incidence of IPD among children <5 years from approximately 
99 cases per 100,000 during 1998-1999 to 21 cases per 100,000 in 2008 (28). 
Data from the last report of ABCs from 2012 (25), indicated 12,8 cases of 
pneumococcal infection per 100,000, with higher rates in children under one year 
of age and adults over 65. Considering the rates of death by this bacterium, in total 
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1,24 cases per 100,000 were reported, with higher rates in adults aged more than 
50 years. 
Considering the high serotype diversity within S. pneumoniae, the high cost of 
these vaccines, and the fact that serotype coverage varies between geographic 
regions, there is the need of developing vaccines that confer broader coverage, 
preferentially independent of the capsular polysaccharide and with a lower cost. 
 
Currently a 15-valent pneumococcal conjugate vaccine (PCV13 serotypes plus 
serotypes 22F and 33F) is in evaluation in an infant-rhesus monkey model (139) 
and a new approach based on whole-cell is also in development (100). 
A vaccine which goal was protection against pneumococcal nasopharyngeal 
colonization was also designed. This vaccine was based in specific antigens that 
activated CD4+ T cells to secrete the cytokine interleukin-17A that mediate 
resistance to mucosal colonization. Recently, was reported that this vaccine was 
tested in a mouse model and showed protection against pneumococcal infection 
(99, 101). 
 
 
EFFECTS OF PNEUMOCOCCAL VACCINATION 
 
Decrease of vaccine serotypes 
In the USA the introduction of PCV7 in the vaccination schedule began shortly 
after the vaccine was licensed, resulting in a decrease of 77% of IPD in vaccinated 
children aged up to 5 years old by 2005 (26). Two years later, Pilishvili et al. 
analyzed IPD cases, identified between January of 1998 and December of 2007, 
in eight participating ABCs in the USA. They reported a decline in IPD incidence of 
76% in children under 5 years old, with a decline around 100% of PCV7 types 
(118). 
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In Europe, Isaacman et al. observed the impact of PCV7 use on the incidence of 
IPD in children from eight countries. The results were variable across studies, with 
the decrease of IPD incidences ranging from 28% to 68%, depending on the 
country, vaccine uptake and the type of disease manifestation (69).  
 
Herd immunity 
The extensive vaccination with PCV7 has also resulted in an indirect protection of 
the non-vaccinated population in all age groups, an effect known as herd immunity 
(26). This was shown for example in a surveillance study conducted in eight areas 
of the USA with adults older than 50 years old, from which Lexau et al. concluded 
that the use of conjugate vaccine in children also benefited the adults included in 
the study, with a decline of 28% in IPD in this age group (89). Herd immunity was 
also reported in newborns, which are too young to receive the vaccine, as 
described by Poehling et al. (119). Also in other countries such as England and 
Wales (98) and Australia (73), herd immunity was detected in the population.  
 
Serotype replacement 
Another effect of pneumococcal vaccination was serotype replacement that results 
from the ability of non-PCV7 serotype strains to fill the niche left vacant by the 
PCV7 serotypes. In several countries, although there was a reduction in IPD cases 
caused by PCV7 serotypes, cases associated to non-PCV7 serotypes increased 
post-PCV7 introduction (3, 5, 63, 64, 69, 86, 118). 
 
The increase of IPD associated to non-PCV7, especially to serotype 19A, was first 
documented by a surveillance study conducted in Massachusetts during 2001 to 
2007 (64). Pilishvili and co-authors also reported that in the USA, between 1998 
and 2007, in ABCs surveillance, the incidence of IPD caused by serotype 19A and 
also other non-PCV7 types increased in all age groups. Serotype 19A increased 
from 0.8 to 2.7 cases per 100,000 and other non-PCV7 types increased from 6.1 
to 7.9 cases per 100,000 (118). However, this increase remains low comparing 
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with the substantial decrease of PCV7 types. In this study the increase in IPD 
caused by non-PCV7 types was more pronounced in meningitis and invasive 
pneumonia, whereas in primary bacteremia there was no change (118). 
Isaacman and co-authors showed also serotype replacement in Europe in a 
review that describes the trends of IPD in European children between 1990 and 
2008. Before the use of PCV7 the serotypes most common recovered in IPD were 
6B, 14, 19F and 23F, although with some variation among countries. After the 
widespread use of PCV, the most common IPD serotypes in Europe were 1, 19A, 
3, 6A and 7F (69).  
 
Recently, a study from Alberta, Canada between 1998 and 2010 encompassing 
PCV7 introduction in the routine vaccination plan, reported that PCV7 types were 
eradicated from IPD in children under two years old and almost eliminated in all 
other age groups (86). On the other hand, they observed an increase in non-PCV7 
serotype IPD, mainly 19A in children and serotypes 5 and 19A in adults (86). The 
authors justify this increase in serotype 5 incidence with the occurrence of an 
outbreak in 2007 (154). Nevertheless, after exclusion of epidemiological data from 
the year 2007, the increase in the IPD cases associated with serotype 5 was still 
significant, compared to the pre-PCV7 era (0.03 per 100,000 versus 0.51 per 
100,000; p<0.001) (86).  
 
However, decrease in IPD incidence and serotype replacement were not observed 
in particular populations. As an example, among the White Mountain Apache in 
Arizona, despite the use of PCV7, high rates of IPD continue to be seen (83). One 
explanation could be the low rates of coverage of this vaccine, only 56.2%, due to 
the fact that the serotypes that were more prevalent in that population are not 
included in PCV7 (83). Interestingly, in this population the rate of 19A has been 
stable or has decreased after vaccination. 
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These observations highlight that replacement of pneumococcal serotypes may be 
related to other factors apart from the introduction of a vaccine. For example, in 
Israel and South Korea, an increase of 19A in IPD was noted before the 
introduction of PCV7 in the market (30, 36). Also, in the study referred to above, in 
Canada, the authors mention that a significant increase of serotype 19A in all ages 
was noticed before the widespread use of PCV7 (86).  
 
The use of PCV7 had also an effect in otitis media, and a global review has been 
recently published by Rodgers et al. (122). In the USA after the introduction of 
PCV7 it has been observed a decrease in the number of PCV7 cases and an 
increase in the number of infections produced by non-PCV7 serotypes, such as 
19A, 3, 6A (122). Another important aspect reported in some studies from 
countries where PCVs were introduced was the decrease in the number of 
medical visits mainly due to otitis and also the number of antibiotic prescriptions 
(14, 114, 161). 
In a study conducted in Israel, with children attending day care centers, children 
vaccinated with PCV9 needed significantly fewer days of antibiotic uptake for 
treating respiratory illnesses and otitis than the control group, vaccinated with 
meningococcal group C vaccine (48).  
 
Antimicrobial resistance  
Antimicrobial resistance rates also suffered some alterations with the introduction 
of PCV7, since the serotypes included in PCV7 tended to have high rates of 
resistance (39). But, as described before, the decreased of PCV7 serotypes varied 
according to the geographic location and vaccine uptake (39, 64, 82).  
 
A good example of how PCV7 could be used to help decreasing antimicrobial 
resistance rates happened in France. In this country, a campaign for the 
rationalization of antimicrobial prescription paralleled vaccination of young children 
with PCV7. Although serotype replacement was observed in carriage and in 
19 
 
disease, the rates of IPD in children less than two years decreased as well as the 
rates of pneumococcal antimicrobial resistance (130, 155). 
 
Invasive pneumococcal disease in Portugal 
In Portugal, serotype replacement in pediatric IPD was also reported (3, 5). 
However, this replacement was not as pronounced as in the USA, where PCV7 
was introduced in the national vaccination program unlike what happens in 
Portugal. Another important aspect was the low coverage of PCV7 in IPD in 
Portugal, mainly due to the high prevalence of serotype 1 compared to the USA. 
The fact that PCV7 is not included in the national vaccination plan and the low 
coverage of this vaccine in IPD in Portugal affect also herd immunity: despite a 
marked reduction in the proportion of IPD in adults caused by PCV7 serotypes, 
they still accounted for 18% of the cases between 2006 and 2008 (63). In the 
same study a decline of serotypes 4, 8 and 14, and an increase of serotypes 1, 7F 
and 19A were observed in adult IPD in the post-PCV7 period. Similar with adults, 
in pediatric IPD, serotypes 1, 19A, 7F, 14 and 3 were the serotypes more 
prevalent in 2006-2008 (3). 
 
Concerning antimicrobial resistance, it remained stable after a small decrease of 
penicillin non-susceptibility in IPD in children under five years old in the first post-
PCV7 years (5). Penicillin non-susceptibility was observed in 18.7% of the isolates 
and resistance to erythromycin was found in 22.9% of the isolates, from which 
18% were NVT (3). On the other hand, in IPD in adults, serotypes 19A and 14 
accounted for the majority of erythromycin and penicillin non-susceptible isolates 
in 2008. Although penicillin non-susceptibility remained stable (17%), resistance to 
erythromycin has been increasing in the post-PCV7 years (63).  
 
7-valent pneumococcal vaccine and carriage 
The first report to show that conjugate pneumococcal vaccines could decrease 
pneumococcal carriage and pneumococcal antibiotic resistance was published in 
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1996. In that study carried out by Dagan et al. the effect of a seven valent 
pneumococcal conjugate vaccine (which included the serotypes: 4, 6B, 9V, 14, 
18C, 19F and 23F conjugated to the outer-membrane protein complex of Neisseria 
meningitis group B) was evaluated in children 12-18 months of age (40). The 
authors observed a decrease of the serotypes included in the vaccine among the 
vaccinated while no changes occurred in the control group. One year after 
vaccination, carriage of antibiotic resistant vaccine-types was still lower in 
vaccinated children than in the control group. After that, a second study conducted 
by the same group was published and both studies showed clearly that conjugate 
vaccine could reduce the carriage and the resistance of pneumococcal serotypes 
included in conjugate vaccines (41).  
Later, Obaro et al., studied the effect of a pentavalent pneumococcal vaccine 
(including serotypes 6B, 14, 18C, 19F and 23F conjugated to CRM197) in infants in 
Gambia and observed the maintenance of high pneumococcal carriage of 
serotypes included in vaccine in control group and a decreased of these serotypes 
in vaccinees. However, an increased of serotypes not included in the vaccine was 
observed in vaccinated children and this effect was not observed in the control 
group (110). This phenomenon of replacement was also observed in a study 
conducted in toddlers attending day-care centers in Southern Israel with 9-valent 
pneumococcal vaccine conjugate with CRM197 (35). 
 
After introduction of PCV7, multiple studies worldwide have demonstrated a 
decrease in nasopharyngeal carriage of PCV7 types and an increased of non-
PCV7 types (39, 49, 66, 116, 125, 137, 156). As observed in IPD the introduction 
of PCV7 interfered with pneumococcal antimicrobial resistance rates, but also 
varied with geographic location, the levels antibiotic consumption and vaccine 
uptake. A pediatric cross-sectional study conducted in Massachusetts, USA (65) 
showed that the vaccine serotypes virtually disappeared in young children, with a 
rapid replacement of non-PCV7 types, which were frequently penicillin non 
susceptible, mainly 19A and 35B. Pelton et al. (116) reported that in two Boston 
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communities serotypes 19F and 6B were the PCV7 types most frequently isolated 
post-PCV7 vaccination, whereas serotypes 4, 9V, 14 and 18C were rarely 
recovered. In Norway, after vaccine introduction, the pneumococcal carriage 
remained high, around 80%, but a decrease in PCV7 serotypes was observed 
(156). In Calgary, Canada a study conducted in seven community health centers 
where routinely PCV7 vaccination began in 2002, a decrease of PCV7 serotypes 
and an increased of non-PCV7 was also observed. In this study the pneumococcal 
carriage rate was low, 20%, and the largest increased of non-PCV7 type was 
noticed in serotypes 6A, 15C, and 11A (75). 
 
Serotype replacement has also been observed in pneumococcal colonization in 
Portugal. The first evidence was in a controlled study conducted before the 
introduction of PCV7 in the market, which included 236 vaccinated children and 
354 control children that attended the same day care center (49). Additionally, a 
reduction on pneumococcal resistance PCV7 serotypes was replaced by an 
increase of resistance in non-PCV7 serotypes (49). Surveillance studies 
conducted after the availability of PCV7 in Portugal also described a marked 
serotype replacement effect in the population (125). Despite serotype 
replacement, maintenance of the antimicrobial resistance rates was observed, due 
to expansion of pre-existent non-PCV7 resistant clones (125, 137). In 2006, five 
years after the introduction of PCV7 in the Portuguese market, non-vaccine types 
1, 6C, 7F, 15A, 16F, 21, 23A, 29, and non-typeable strains (NT) increased 
significantly. A non-significant increase of serotype 19A was also noticed (125). In 
2006 and 2007, the major serotypes were 6A, 6C, 14, 15A, 19A, 19F, 23F and 
non-typeable strains. A significant decrease in clonal diversity was observed for 
serotypes 14 and 19F, whereas a significant increase in clonal diversity was 
observed for serotype 6C and non-typeable strains. For serotypes 6A and 19A no 
significant changes in clonal diversity occurred with introduction of PCV7 (137).  
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All the above mentioned studies were conducted in the Lisbon area; in order to 
evaluate if this data would be representative of the country, surveillance initiatives 
were expanded to other areas of Portugal and the results are in Chapters III and 
IV of this thesis. 
Recently, a study published by Valente et al. suggested a novel potential benefit of 
conjugate vaccines. In the study the effect of PCV7 on pneumococcal co-
colonization was evaluated. Lower co-colonization rates were observed among 
fully vaccinated children when compared with unvaccinated children. Since a 
decrease of co-colonization could translate in lower opportunities for horizontal 
gene transfer, this effect may function as a “brake” for capsular switch or 
acquisition of resistant genes (151). 
 
 
PERSPECTIVES FOR PCV10 AND PCV13 
 
The introduction of PCV10 and PCV13 is expected to have an impact on 
pneumococcal disease and carriage. In 2010, a study conducted in the USA 
predicted the effectiveness of PCV13 from observed PCV7 data. According to their 
model PCV13 would prevent 106,000 invasive pneumococcal disease cases and 
2.9 million pneumonia cases over a 10-year period (124). Recently, another study 
examined public-health and economic impacts of PCV pediatric national 
immunization programs in Germany, Greece and The Netherlands and estimated 
that PCV13 would eliminate 31.7%, 46.4%, and 33.8% of IPD in Germany, 
Greece, and The Netherlands, respectively. PCV13 was found to be cost-effective 
or cost saving when compared to PCV7 and PCV10 (147).  
 
The use of the polysaccharide vaccine (PPV23) remains controversial, as 
described by Huss et al. in a recent meta-analysis (67). In this meta-analysis 22 
trials were included. The authors analyzed several databases, all reports of 
reviews and meta-analysis for clinical trials that compared the use of PPV with a 
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control. The vaccine efficacy on clinical outcomes and the quality of the 
methodology used in the trials were evaluated. For the authors in all trials 
analyzed there was little evidence of protection of this vaccine against the elderly 
or in adults with chronic disease. This vaccine seems not to be effective for 
prevention of pneumonia, even in countries where it is currently recommended. 
Recently, PCV13 has been approved for prevention of pneumonia and invasive 
disease caused by PCV13 serotypes among adults aged 50 years and older (27). 
However, the efficacy of this vaccine in this age group has not been established 
yet. A trial is in progress in The Netherlands involving 85,000 persons aged 65 
years and older (56). Nevertheless, the full impact of PCV13 in children and in 
adults is not known yet.  
 
 
PNEUMOCOCCAL TYPING METHODS 
 
In the era of pneumococcal vaccines, with several and rapid changes in the 
pneumococcal population is important and essential to have good and adequate 
typing methods. 
 
The choice of a typing method will depend upon the needs, skill level, and the 
resources of the laboratory. An optimal typing method should show high 
typeability, adequate stability, high reproducibility and high discriminative power. 
Additionally, ease of use and interpretation, quick, and low cost are also 
convenient criteria. 
 
Typing pneumococcus has been useful for understanding the evolution of the 
species, in epidemiological studies and also in outbreak cases (153).  
Characteristics expressed by the microorganism permit to classify them by 
phenotyping methods. Methods that involve direct DNA-based analysis of 
chromosomal or extra-chromossomal genetic determinants are considering 
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genotyping methods. In general, genotyping methods have higher discriminative 
power and higher typeability than phenotyping methods and constitute the best 
approach for bacterial comparison. 
 
Antibiotyping 
Antibiotyping consists of an antimicrobial susceptibility testing where the isolates 
are tested by diffusion or dilution methods against a panel of antimicrobial agents. 
The results are interpreted according to international guidelines. This technique is 
easy to perform, gives rapid results, it is cheap and readily available in the routine 
microbiology laboratories. However, the major disadvantage is the poor 
discriminative power for typing proposes. Antibiotic resistance patterns are, to 
some extent, influenced by the local environment and the antibiotic pressure (81). 
 
Pneumococcal serotyping 
This method consists of a reaction of the capsule polysaccharides with polyclonal 
factor sera (145) and recently, also with the use of monoclonal antibodies (21). 
Classical serotyping is performed using the Quellung or Neufeld reaction (10). 
With this assay the swelling of the capsule of the pneumococcus is observed using 
a contrast phase microscope after mixing the bacteria with serotype specific 
antiserum. The assay includes one chessboard sequential testing of antisera of a 
pool that gives a serogroup, and then a specific factor serum that gives the 
serotype. The bacteria will frequently also agglutinate. The subjectivity in 
interpretation, the high cost of antisera, the need for a complete set of control 
strains, and technical expertise requirements associated with these serologic 
methods have resulted in development of PCR based serotyping systems (17).  
 
Several other methods for pneumococcal serotyping have been described, such 
as coagglutination, enzyme–linked immunosorbent assay and 
countrimmunoelectrophoresis (9, 85, 160). However, the sensitivity, specificity and 
the fact that they are very laborious do not make these methods a good alternative 
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to Quellung reaction. Latex agglutination tests also have been developed since at 
least 1988 (84). However, only in 2004 Slotved et al. (142) developed a simple, 
rapid latex agglutination test (Pneumotest-Latex), which is used nowadays in 
several laboratories. 
More recently, a PCR scheme using a sequential series of multiplex PCRs to 
assess serotypes or related sets of serotypes has been developed by the CDC 
(113) (www.cdc.org). The use of this approach to assess the serotype is 
convenient because of the relatively low cost compared to the classic method and 
the time consumed.  
 
Recently, Elberse et al., described a new genotyping method, capsular sequence 
typing (CST), based on the determination of the partial sequence of the capsular 
wzh gene, using a single PCR reaction with multiple primer sets (46). Another 
promising methodology published for serotyping pneumococci is based on three 
multiplex PCR combined with fragment analysis and automated fluorescent 
capillary electrophoresis (FAF-mPCR) which detects a great number of 
serotypes/serogroups. Although it does not differentiate some groups of serotypes, 
this automatic method allows the analysis of 30 samples in a few hours and at low 
cost (133). 
 
Additionally, some isolates do not react with any commercially available antiserum. 
These atypical isolates are called non-typeable S. pneumoniae (NTPn). These 
isolates are difficult to identify as their differentiation from closely related species 
such as Streptococcus pseudopneumoniae and other streptococcus of the mitis 
group is not always straightforward. Recently, Simões et al. (138) developed a low 
cost and easy assay to detect NTPn. The strategy is based on a multiplex PCR 
targeting lytA, cpsA, aliB-like ORF2 and 16S rDNA genes, plus a RFLP assay to 
differentiate typical from atypical lytA. 
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PFGE and MLST 
Currently, the gold standard genotyping methods for pneumococci are pulsed-field 
gel electrophoresis (PFGE) (132) and multilocus sequence typing (MLST) (47). 
 
Pulsed-field gel electrophoresis (PFGE) was developed in 1984 by Schwartz and 
Cantor (132) and is based on the digestion of the total chromosomal DNA with a 
restriction endonuclease that cleaves the DNA infrequently. The macro-restriction 
fragments are separated by gel electrophoresis according to molecular weight in 
an apparatus which voltage is periodically switched among three directions. The 
different orientation of the electric pulses during electrophoresis allows the 
separation of large DNA fragments. Normally the total chromosomal DNA of S. 
pneumoniae is digested with SmaI and 10 to 19 bands of 20 to 300 kb are 
obtained (87). This technique is inexpensive, shows a good typeability, 
reproducibility, and a good discriminative power. However, it is time consuming 
and standardization of the method and good quality of the gels are pre-requisites 
to compare results between laboratories. Despite established interpretation criteria 
by visual comparison (148) and the standardization of the method (31) the 
comparison of results remains sometimes difficult. As an alternative to visual 
classification, automatic methods that use band-based similarity coefficient to 
classify by type/subtype the microbial isolates analyzed by PFGE have been 
developed. Carriço et al. demonstrated a good correspondence between visual 
and automatic classification for S. pneumoniae (24).  
 
MLST for pneumococci is a nucleotide sequence based approach that includes 
PCR amplification and sequencing of ~450-bp internal fragments of seven 
housekeeping genes: aroE - shikimate dehydrogenase, gdh - glucose-6-
phosphate dehydrogenase, gki – glucose kinase, recP - transketolase, spi – signal 
peptidase, xpt – xanthine phosphoribosyltransferase, and ddl – D-alanine-D-
alanine ligase (47). The sequence of each allele is compared to all know alleles 
available online in an international database (www.mlst.net), and each allele is 
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assigned with a number. The combination of the seven numbers defines the allelic 
profile or sequence type (ST). The major advantage of this technique is the 
unambiguous ability to compare the results obtained in different laboratories, using 
the online database. However, this method is time consuming if need to analyze a 
big collection and expensive for laboratories without a sequencer. MLST has a 
good discriminative power and is a good tool for local and global epidemiology.  
 
MLVA 
Multiple-Locus Variable number tandem repeat Analysis (MLVA) is based in 
repetitive DNA localized in multiple loci of all bacterial genome. The number of 
repeat sequences and the sizes of these units, named BOX elements, may vary 
for different isolates of the same species. These BOX elements were identified in 
the genome of the pneumococcus in 1992 (94). In the genome of prototype strains 
R6 and TIGR4 115 and 127 BOX elements, have been found, respectively. The 
function and origin of BOX elements are unknown; however, it is thought that they 
may be involved in regulating the expression of virulence-associated genes when 
they are located in the promoter region of genes (78, 94). Van Belkum and 
colleagues were the first to show the usefulness of these repeats for genotyping S. 
pneumoniae using PCR-BOX. However the banding profiles were difficult to 
interpret and often lacked reproducibility (152). The first MLVA scheme based on 
BOX typing applied to pneumococcus was developed by Koeck et al. in 2005 (79). 
In this scheme 16 BOX loci are analyzed after amplification in a single PCR 
reaction and the product are visualized by agarose gel electrophoresis. This 
technique has high congruence with MLST and shows high discriminative power, 
providing a good alternative to MLST. Although it allows for the comparison of data 
between laboratories using a website (www.mlva.eu), this scheme and the use of 
agarose gel electrophoresis makes this method very fastidious. A new scheme 
and easier protocol was needed and is described in chapter VI of this thesis. 
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Whole genome sequencing 
The sequencing of whole genomes (WGS) represents a great advance for the 
study of bacterial populations because current approaches such as MLST are 
based on the analysis of only seven housekeeping gene fragments amounting 
only less than 0,2% of the total length of the genome. Horizontal gene transfer 
(HGT) is a fundamental process in bacterial genome evolution where a great 
portion of DNA can be incorporated from another species genome. Since S. 
pneumoniae is naturally transformable these events occur frequently. Small-scale 
mutations as substitutions, deletions or insertions could also occur. With this 
technique all these events can be identified by comparing the sequences with a 
reference genome. These differences in the core genome allow the construction of 
phylogenetic trees to show the evolutionary relationships among the isolates of the 
same species. WGS can also be useful in epidemiological studies, namely to 
follow the spread of a clone which isolates seem to be identical in several 
countries. One example of this was demonstrated with the genome sequencing of 
several isolates of the international multiresistant Spain23F-1 clone, which showed 
that the genome sequence of each isolate differs slightly and these differences 
represent an evolution of the specie, which was impossible to evaluate without 
WGS (34). 
 
In addition WGS has the capacity to simultaneously elucidate serotype (if the 
capsule is expressed), sequence type and details of genetic information, which 
provide a good approach to monitor the impact of pneumococcal vaccines.  
 
Recently, Golubchick et al. reported that using whole-genome resequencing 
allowed them to identify five independent occurrences of vaccine escape through 
capsular switches between serotype 4, which is included in PCV7, by serotype 
19A that is not. By using WGS the authors were able to search for putative donor 
and recipient genomes and demonstrated the independent origin of each 
recombinant lineage. Their results also reinforced the idea that during a single 
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episode of recombination multiple and large additional DNA fragments can be 
imported (52).  
Although very promising the price of WGS remains high and the bioinformatic tools 
for data analysis need further development for routine use by hospitals and by 
scientific community in general like as mention by Török et al. (150). 
 
 
AIM OF THE WORK 
 
The aims of this thesis were to gain insights into: (i) the epidemiology of the 
recently discovered serotype 6C, (ii) the pneumococcal colonization patterns in 
different regions of Portugal among healthy children and (iii) the pneumococcal 
colonization patterns in the elderly. Additionally, the need for the development and 
validation of easier and faster methods of molecular typing was also addressed. 
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Abstract  
We studied the epidemiology of the recently described serotype 6C of 
Streptococcus pneumoniae among a collection of carriage isolates recovered 
between 1996 and 2007 in Portugal. Of 4,064 isolates, 106 (2.6%) were of 
serotype 6C of which 17.9% were multidrug resistant. The strains were genetically 
diverse.  
 
Introduction  
The polysaccharide capsule of Streptococcus pneumoniae is considered the most 
important virulence factor in this species. It is antigenically diverse and its 
identification by serology (Quellung reaction) has been used for decades as a 
primary criterion for classification of pneumococci (18). Up to now 91 serotypes 
have been described being 6C the most recent one (14). The latter is 
indistinguishable from 6A by the Quellung reaction although it contains a galactose 
molecule instead of a glucose in the capsular repeating oligosaccharide unit due to 
the presence of a different glycosyl transferase (wciN) gene (14). Serotypes 6A 
and 6C, together with serotype 6B constitute the serogroup 6 which has related 
capsular structures (1, 10). A putative serotype 6D that would result from the 
introduction of wciN6C in the 6B operon has been proposed although it remains 
unidentified (7). 
 
The 7-valent pneumococcal conjugate vaccine (PCV7, targeting serotypes 4, 6B, 
9V, 14, 18C, 19F and 23F) was introduced in the USA in 2000 and became 
commercially available in several European countries during 2001. PCV7 confers 
protection, within serogroup 6, against serotype 6B.  The most recent available 
data suggest it provides cross-protection to disease caused by serotype 6A but not 
serotype 6C (12). 
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Due to its recent identification, data on the epidemiology of serotype 6C are still 
very scarce (13). A recent study from South Africa found that serotype 6C strains 
had a higher propensity to cause meningitis than serotypes 6A or 6B (5). A study 
from the CDC in the United States reported that in 2006 the rate of invasive 
disease caused by serotype 6C was significantly higher than in 1999 but lower for 
serotype 6A (3). Another very recent publication from the USA also documented 
the increasing prevalence of this serotype after 2001 (8). 
 
In this study, we describe the epidemiology of serotype 6C strains colonizing 
healthy preschool Portuguese children in studies conducted between 1996 and 
2007.  
 
Materials and Methods 
We screened 4,064 S. pneumoniae strains isolated from a total of 6,559 
nasopharyngeal samples obtained from children attending day-care centers (DCC) 
in Lisbon and Oeiras areas, Portugal, in studies conducted in nine different years, 
between 1996 and 2007: 1996-1999, 2001-2003, and 2006-2007. All samples 
were collected between January and March of each year. Identification of 
pneumococci was done as previously described (17). The serotypes of drug-
resistant isolates (n=1,659) have been reported (9, 11, 16, 17).  
 
Antimicrobial susceptibility testing was performed using the Kirby-Bauer technique, 
according to the Clinical and Laboratory Standards Institute (4) recommendations 
and definitions (4) for chloramphenicol, erythromycin, clindamycin, tetracycline, 
and sulfamethoxazole-trimethoprim (SXT). MICs of penicillin and ceftriaxone were 
determined with E-test (AB Biodisk, Solna, Sweden) according to the 
manufacturer’s recommendations and interpreted according to CLSI guidelines 
(4). Multidrug resistance was defined as resistance to three or more antibiotics 
tested. 
57 
To identify strains of serogroup 6, all isolates lacking serotype assignment were 
screened by PCR for the presence of a specific region of wzy gene as described 
(2). Specifically, two primer pairs were used, 6Bwzy-f (5’-CGA CGT AAC AAA 
GAA CTA GGT GCT GAA AC-3’) and 6Bwzy-r (5’- AAG TAT ATA ACC CTG TAA 
AAC TCT GAC-3’), generating a product of 200 bp for all serogroup 6 strains, and 
cpsA-f (5’-GGT GTT CTC TAT CCT TGT CAG CTC TGT GTC GCT C-3’) and 
cpsA-r (5’-GTG TGA ATG GTC GAA TCA ACT CTA TAA ATG CC-3’), generating 
a product of 657 bp. The highly conserved gene cpsA exists in all but two capsular 
loci and was used as internal control (2). To assign serotypes 6A, 6B, and 6C (and 
the putative 6D) all serogroup 6 isolates were (i) typed by the Quellung reaction 
(18) and (ii) screened by PCR for a region of wciN, using previously described 
primers (5’-TACCATGCAGGGTGGAATGT-3’ and 5’-CCATCCTTCGAGTATTGC-
3’) that result in a product size of 2.0 kb for serotypes 6A and 6B and of 1.8 kb for 
serotype 6C (13). The PCR reactions were done in a 10 µl volume with 1x GoTaq® 
Flexi Buffer (Promega, Madison, USA), 2.5 mM of MgCl2, 0.08 mM of dNTPs, 1.0 
µM of each primer,  and 0.1 Uµl-1 of GoTaq® Flexi DNA Polymerase (Promega, 
Madison, USA). DNA was isolated from freshly grown bacterial cultures, picked 
with a sterile tip, and briefly immersed in the PCR reaction mix. Thermocycling 
was performed in My Cycler thermal cycler (Bio-Rad Laboratories, Hercules, 
California) with the following conditions: 94ºC for 4 min; 35 cycles of 94ºC for 30 s, 
60ºC for 45 s and 72ºC for 45 s (for wzy) or 2 min (for wciN); and a final extension 
step at 72ºC for 5 min. PCR analysis was done by electrophoresis on 1% or 2% 
Seakem LE agarose gels in 1x TAE buffer. Gels were stained in a 0.1 µg ml-1 
ethidium bromide solution. 
 
Preparation of chromosomal DNA, restriction with SmaI endonuclease, PFGE, and 
analysis of patterns with Bionumerics software (version 5.10, Applied Maths, Gent, 
Belgium) were done as previously described (15, 17). Multilocus sequence typing 
(MLST) was performed  as previously described (6) on selected strains of each 
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PFGE cluster, choosing within each group, at least one representative of each 
year.  
 
Results and discussion 
Out of 4,064 pneumococci strains recovered from colonization samples in studies 
conducted between 1996 and 2007, 809 (19.9%) were of serogroup 6: 7.3% were 
of serotype 6A, 9.6% were of serotype 6B, and 2.6% were of serotype 6C. 
Temporal fluctuations were observed for all serotypes (Table 1). Serotype 6B was 
dominant among serogroup 6 isolates from 1996 until 2002, when it started to 
decline, being almost absent by 2006. For serotype 6A a sharp decrease was 
observed in 1998 and no significant fluctuations were observed with the availability 
of PCV7 (since June 2001). Serotype 6C ranged from 0.2% to 5.8% reaching the 
highest value in 2007. There were no strains of the hypothetic serotype 6D.  
 
Of the 106 serotype 6C strains identified, 35.8% were resistant to at least one of 
the antibiotics tested. The proportion of penicillin-resistant isolates according to 
parenteral meningeal and non-meningeal criteria was 30.2% and 0%, respectively, 
as 29.2% of the 106 isolates had a MIC of 0.12µg ml-1 and a single isolate (1%) 
had a MIC of 0.25 µg ml-1 (4). Resistance levels were 21.7% for erythromycin, 
18.9% for clindamycin, 18.9% for tetracycline and 1.9% for SXT. Multidrug 
resistance was detected in 17.9% of the isolates and was observed in 2006 and 
2007 only. 
 
PFGE fingerprint clustered the 106 serotype 6C strains into eleven groups 
(Table 2). By MLST, the 27 strains representing all PFGE groups yielded 11 
sequence types STs that, using eBURST (20) and the complete database of S. 
pneumoniae (available at http://spneumoniae.mlst.net/), fell into four clonal 
complexes based on a minimum similarity of five identical loci (numbered by ST of 
the predicted founder as CC138, CC395, CC386, and CC3034) and two singletons 
59 
(STs 3671 and 2789) (Table 2). Three novel STs were found in this study (3671, 
3673, and 3711). 
The dominant group 6C-1 (STs 395, 1692, 1714, and 3711) included 52 strains 
susceptible to all antibiotics that were recovered from several day-care centers 
and were detected in all but one sampling period (Figure 1 and Table 2). The next 
two most frequent groups 6C-2 (ST1150, 18 isolates) and 6C-10 (ST3396, 11 
isolates) contained strains resistant to penicillin (according to meningeal criteria). 
 
TABLE 1. Distribution of serogroup 6 pneumococci over time 
Year 
Total 
no. Pn 
isolates 
No. of isolates (%) 
SG 6 6A 6B 6C 
1996 277 77 (27.8) 33 (11.9) 40 (14.4) 4 (1.4) 
1997 353 84 (23.8) 26 (7.4) 46 (13.0) 12 (3.4) 
1998 465 66 (14.2) 5 (1.1) 60 (12.9) 1 (0.2) 
1999 596 137 (23.0) 45 (7.6) 68 (11.4) 24 (4.0) 
2001 466 135 (29.0) 57 (12.2) 75 (16.1) 3 (0.6) 
2002 559 97 (17.4) 30 (5.4) 61 (10.9) 6 (1.1) 
2003 559 94 (16.8) 41 (7.3) 36 (6.4) 17 (3.0) 
2006 392 64 (16.3) 46 (11.7) 2 (0.5) 16 (4.1) 
2007 397 55 (13.8) 31 (7.8) 1 (0.3) 23 (5.8) 
Total 4,064 809 (19.9) 314 (7.3) 389 (9.6) 106 (2.6) 
Pn – pneumococci; SG - Serogroup 
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TABLE 2. Characteristics of serotype 6C strains  
PFGE group 
(no. of isolates)  
ST 
(no. of isolates)a  CC  
Resistance pattern 
(no. of isolates)  
No. of 
DCC  
6C-1 (52)  ST395 (5)  395  Susceptible  12  
ST1714 (1)  
ST1692 (1)  
ST3711 (1)  
6C-2 (18)  ST1150 (4)  138  P (11)  3  
Susceptible (7)  
6C-3 (1)  ST1150 (1)  138  P  1  
6C-4 (4)  ST3673 (2)  138  Ery  2  
6C-5 (1)  ST2789 (1)  Singleton  Susceptible  1  
6C-6 (2)  ST3671 (1)  Singleton  Susceptible  1  
6C-7 (6)  ST1150 (1)  138  P (3)  3  
ST2689 (2)  Susceptible (3)  
6C-8 (2)  ST2185 (1)  3034  Ery, Clin, Tet, SXT  1  
6C-9 (3)  ST395 (2)  395  Susceptible  1  
6C-10 (11)  ST3396 (1)  386  P, Ery, Clin, Tet (8)  1  
Ery, Clin, Tet (3)  
6C-11 (6)  ST3396 (1)  386  P, Ery, Clin, Tet  1  
P, penicillin G MIC of 0.12 µg ml-1 with the exception of a single isolate that had an MIC of 
0.25 µg ml-1; Ery, erythromycin; Clin, clindamycin; Tet, tetracycline; SXT, trimethoprim-
sulfamethoxazole; No. of DCC, number of day-care centers where PFGE group was found. 
aNumber of representative strains tested. 
 
The dominant group 6C-1 (STs 395, 1692, 1714, and 3711) included 52 strains 
susceptible to all antibiotics that were recovered from several day-care centers 
and were detected in all but one sampling period (Figure 1 and Table 2). The next 
two most frequent groups 6C-2 (ST1150, 18 isolates) and 6C-10 (ST3396, 11 
61 
isolates) contained strains resistant to penicillin (according to meningeal criteria). 
In addition, strains of group 6C-10 were also resistant to erythromycin, clindamycin 
and tetracycline (Table 2). While group 6C-2 was found in 1997 and between 2001 
and 2003, group 6C-10 was identified in 2007 only (Figure 1). The remaining eight 
groups were sporadic representing 0.9-5.7% of the serotype 6C collection. 
 
Our study shows that the recently described serotype 6C is frequently carried by 
healthy young children in Portugal. Overall, of all isolates that would have been 
conventionally typed by the Quellung reaction as serotype 6A, close to one-quarter 
(25.2%) were identified as serotype 6C; this value ranged between 5.0% and 
42.6% depending on the sampling period.  
 
FIG 1. Distribution of serotype 6C PFGE clones through the nine study periods. 
MDR, multidrug resistant. 
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Serotype 6C strains circulating in Portugal are genetically diverse. Similar 
observations were recently reported in a USA study (8) and, of interest, there were 
no common STs among serotype 6C isolates from both studies.  This observation 
implies that, if the introduction of wciN6C in the capsular operon of 6A occurred only 
once as suggested by Park et al., it must have occurred a sufficiently long time 
ago to yield such lineage diversity (13). In our collection, one fully antibiotic-
susceptible lineage (6C-1, STs 395, 1692, 1714, and 3711) persisted over one 
decade and accounted for close to half of all serotype 6C isolates suggesting it is 
well adapted even when considering the natural selection driven by antibiotic 
pressure. Still, strains of serotype 6C circulating in Portugal are often drug-
resistant and, in particular, multidrug resistance has been detected in 2006 and 
2007. These data contrast with recent observations from South Africa where most 
invasive strains of this serotype were fully susceptible or resistant to macrolides 
only, but are comparable to resistance rates reported in a recent study from the 
USA (8). 
 
Conclusion  
In summary, serotype 6C circulates in Portugal at least since 1996. It is genetically 
diverse and often antibiotic resistant. Continued surveillance of this serotype is 
important since it is not targeted by PCV7 and is not known if PCV13 (which 
targets not only 6B but also 6A) will confer cross-protection to it. Additional data 
from other countries and estimates of its invasive disease potential will help us 
understand the epidemiology of this serotype. 
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ABSTRACT 
  
The seven-valent pneumococcal conjugate vaccine (PCV7) became available in 
Portugal in 2001. Although not included in the national immunization program, 
vaccination coverage is high (over 60%). We studied for the first time the rates of 
nasopharyngeal (NP) carriage of pneumococci, antibiotic resistance patterns and 
serotypes among children attending day care centers (DCCs) in Coimbra, a city in 
the Central Region of Portugal. Between January and February 2007, a cross-
sectional study was conducted among children aged 6 months to 6 years old 
attending eight DCC. NP swabs were obtained from 507 children: 76.7% had 
received at least one dose of PCV7 and 64.3% were age-appropriately vaccinated. 
The global pneumococcal carriage rate was 61.3%. Colonization proportions 
varied with age and number of children attending each DCC. Serotyping revealed 
that 20.7% of the pneumococci were vaccine types (VT), 70.8% were non-vaccine 
types (NVT), and 8.5% were non-typeable. Serotype 19F was the second most 
frequent serotype being detected in 10.5% of the samples. While global NP 
carriage was not associated with vaccination status, NVT were predominant 
among vaccinated children, who had significantly lower prevalence of VT. Of all 
isolates, 15.7% had penicillin MICs that ranged between 0.12 and 2 µg/ml. The 
proportion of resistant strains was significantly higher among VT and unvaccinated 
children. In conclusion, the rates of vaccination and prevalence of pneumococcal 
NP were high. Rates of antimicrobial resistance were similar to those found in 
studies conducted in Oeiras and Lisbon. This study is a platform for future 
surveillance activities.  
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INTRODUCTION  
 
Pneumococcus is a leading cause of invasive and noninvasive disease among 
children worldwide. The importance of pneumococcal infections is highlighted by 
an increasing prevalence of drug-resistant strains (28, 34, 45). 
 
A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in the USA in 
2000. Pneumococcal conjugate vaccines (PCVs) have been shown to be highly 
efficacious against vaccine-type (VT) serotypes invasive pneumococcal disease 
(IPD). They are also efficacious against chest radiograph–confirmed pneumonia 
and otitis media (OM) (2, 6, 9, 12, 24, 31). Increase in NVT pneumococcal disease 
has been observed among some age groups in invasive-disease (16, 21) and in 
OM efficacy trials (12, 23). 
  
Because NP carriage is a precondition for developing disease, and it is this 
condition, rather than pneumococcal disease, that results in person to person 
pneumococcal transmission, it is essential to thoroughly understand the impact of 
PCV on NP colonization. Conjugate vaccines are thought to reduce VT 
pneumococcal carriage by preventing new acquisitions, rather than by terminating 
existing carriage episodes (8), although the mechanism is incompletely 
understood. Reductions in VT pneumococcal carriage may prevent disease 
among unvaccinated individuals by decreasing the transmission of these 
serotypes in the community (7, 33, 44). Numerous studies have shown that 
conjugate vaccines protect against VT carriage in the months immediately after 
vaccination (27, 28, 32) and more recently Millar et al. showed that community-
wide PCV7 vaccination in infancy reduces the prevalence of VT carriage and 
increases the prevalence of NVT carriage (serotype replacement)  through at least 
3 years of age (28). The indirect protective effects against VTs (herd immunity) 
and the indirect and direct replacement effects result in large part from the impact 
of PCV on NP colonization (30). 
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Day-care centers (DCCs), for preschool children are unique settings for the spread 
of pneumococcal carriage. DCC attendance has been found to be an important 
risk factor for development of IPD in children and infants (25, 43). The role of 
DCCs in the transmission of S. pneumoniae to the community is also well 
documented (19). 
 
PCV7 became available in Portugal in 2001 but has not been included in the 
national vaccination program. Thus, vaccines are given after medical prescription 
and paid by the parents and not reimbursed by the National Health Service. Two 
studies reported vaccination coverage values (10, 35) among children within the 
age group attending DCC, but samples were not representative of the whole 
population. Portugal has high antibiotic consumption (17) and penicillin non-
susceptible S. pneumoniae are frequently isolated (1, 37). Previous colonization 
studies in Portuguese DCCs, were conducted in the areas of Lisbon and Oeiras 
(26, 29, 36). 
 
This study intended to estimate the prevalence of NP carriage of pneumococci, 
identifying serotype distribution and antibiotic resistance patterns among children 
attending DCCs, in the era of widespread use of PCV7, in Coimbra, a city in the 
central region of Portugal, 200 Km away from Lisbon.  
 
 
METHODS 
 
Study population  
A convenience sample of four urban and four suburban DCCs was selected. The 
target population consisted of 660 children, aged 6 months to 6 years old, 
attending eight DCCs in Coimbra, a city in the central region of Portugal.  
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Study design and approval  
A cross-sectional study was performed in January and February of 2007. The 
study was approved by the Ethical Committee of Hospital Pediátrico de Coimbra. 
Parents or guardians provided written informed consent for their child to 
participate. 
 
Questionnaire  
One week before sample collection, the following information was obtained from a 
questionnaire filled in by the parents or guardians of participating children: age of 
the child, number of children in the household who were ≤6 years of age, presence 
of any underlying illness, presence of a cigarette smoker at home, use of 
antibiotics in the preceding month, maternal educational level and dates of all 
PCV7 doses received. In the few cases where the number of doses was reported 
without vaccination dates, the parents were contacted either by one of the 
investigators by phone or by the nurses during the sample collection visit. 
 
Vaccination status  
Vaccination with PCV7 was considered appropriate if it was done according to one 
of the following schemes: a 4-dose series if starting vaccination at 2 months of 
age; a 3-dose series if starting vaccination at 7-11 months of age; a 2-dose series 
if starting vaccination at 12-24 months of age and 1 dose if starting vaccination at 
≥ 24 months, as recommended by the vaccine manufacturer. A child was defined 
as age-appropriately vaccinated if at the time of sampling had received all 
recommended doses, according to the age at initiation of vaccination. Those with 
fewer doses than recommended by age at initiation of vaccination were classified 
as partially vaccinated. Doses of PCV7 received during the four weeks that 
preceded sampling were not considered for the vaccination status classification.  
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Sample collection and isolation of pneumococci  
Nasopharyngeal samples were obtained by trained nurses with a small flexible 
swab (BBL Culture Swab; Becton-Dickinson, Sparks, MD) inserted through the 
nostril until resistance was encountered. The swab was then removed and 
inoculated into the transport medium (Stuart medium) and transported at ambient 
temperature to the Laboratory of Microbiology at Centro Hospitalar de Coimbra 
and was stored at 4°C for a maximum of 12 hours before samples were plated. 
Specimens were streaked onto tryptic soy 5% sheep blood agar plates (Becton 
Dickinson) and incubated overnight at 37°C in 5% CO2. Phenotypic characteristics 
(morphology and α-hemolysis) were used for the presumptive identification of 
pneumococci. Pneumococcal identification was confirmed by optochin 
susceptibility and bile solubility assays (29). When suspected pneumococcal 
colonies with more than one morphology were observed, each type was purified 
for further testing. Isolates were frozen and stored at -70ºC. 
 
Antimicrobial susceptibility testing  
Susceptibility of all isolates was tested by the disk diffusion method in accordance 
with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (5), 
against erythromycin, clindamycin, tetracycline, chloramphenicol, 
sulfamethoxazole-trimethoprim (SXT), levofloxacin, and vancomycin (Becton-
Dickinson). Minimum inhibitory concentrations (MICs) of penicillin and cefotaxime 
were determined by E-test (AB Biodisk, Solna, Sweden) according to the 
manufacturer’s recommendations. Interpretation of penicillin and cefotaxime MICs 
followed CLSI criteria (5). 
 
Serotyping  
Pneumococci were serotyped by the Quellung reaction using commercially 
available antisera (Statens Serum Institut, Copenhagen, Denmark) (41). Serotypes 
were grouped into one of three categories: (1) vaccine type (VT; i.e., types 4, 6B, 
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9V, 14, 18C, 19F, and 23F); (2) non-vaccine type (NVT) and (3) non-typeable 
(NT). 
 
Pulsed-field gel electrophoresis (PFGE)  
Pneumococci strains that were resistant to at least one of the antibiotics tested, 
were also typed by PFGE. All strains with penicillin MICs ≥0.12 µg/ml were 
analyzed. Preparation of chromosomal DNA, restriction with SmaI endonuclease, 
and PFGE were done as previously described by Sá-Leão et al. (39). PFGE 
patterns were analyzed with Bionumerics software (version 5.10, Applied Maths, 
Gent, Belgium). Patterns were clustered by UPGMA, and a dendrogram was 
generated from a similarity matrix calculated using the Dice similarity coefficient 
with an optimization of 1.0% and a tolerance of 1.5%. PFGE clusters were defined 
as isolates with a similarity of 80% or higher on the dendrogram (38). 
 
Statistical analysis  
Univariate analysis was done using Epi Info 2000 (11). Chi-square tests with Yates 
correction were used. Multivariate analysis, with carriage status of S. pneumoniae 
as the dependent variable, was done using a logistic regression model fitted by 
Stata (42). Population diversity was measured by calculating the Simpson´s Index 
of Diversity (SID) with 95% confidence intervals (CI) for drug-resistant NVT and VT 
strains. Congruence between PFGE clones and DCCs was evaluated with the 
Adjusted Rand (AR) coefficients (4). 
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RESULTS  
 
General characteristics of the study group  
A NP swab was obtained in 507 (77%) of the 660 children attending the eight 
DCC. Between 19 and 113 children were tested at each DCC. General 
characteristics of the study group at the time of sampling are described in Table 1. 
The mean age of participants was 40.6 months (range 6.1 to 80.9 months) and 
262 (51.7%) were male; 148 (29%) had siblings ≤ 6 years of age and none had 
more than two siblings in that age group. Using maternal educational level as a 
proxy for socio-economic level, it was observed that more than 74.2% of the 
mothers had more than the compulsory schooling level in Portugal (nine years). 
The use of an antibiotic within one month prior to study enrollment was reported 
for 126 (24.9%) children; 29.9% lived with one or more cigarette smoker.  
 
Vaccination status 
Three hundred and eighty nine children (76.7%) had received one to four doses of 
PCV7; 64.5% (327/507) were classified as age-appropriately vaccinated and 
12.3% participants had not completed the schedule recommended by the 
manufacturer and were classified as partially vaccinated (Table 2). A higher 
proportion of age-appropriately vaccinated children was observed among children 
aged 6-12 months, decreasing thereafter to a minimum at the age group older 
than 60 months (Figure 1). 
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Fig. 1. Vaccination status according to the age group 
 
Carriage 
The global carriage rate was 61.3% (311/507). Pneumococcal colonization 
proportions varied with age (p<0.0001); among children below one year of age, 
57.9% were colonized, and the peak (76.2%) was observed among children 12–24 
months; from this age group on the proportion of colonized children decreased 
gradually to the older age groups (p<0.000001 in Chi-square test for linear trend), 
reaching the minimum level of 47.0% among the older age group (Table 1 and 
Figure 2). 
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Table 1. Characteristics of the study group and univariate analysis of factors 
associated with Streptococcus pneumoniae colonization
 
PCV7, 7-valent pneumococcal conjugate vaccine; SP, Streptococcus pneumoniae 
 
 
 
 
 
 
Characteristics / 
factors
Category
Non-SP colonization
(n=196 )
SP colonization
(n=311)
Total SP
(n=507)
p-value 
(χ2 test)
Sex Male
Female
99 (40.4%)
97 (37.0%)
146 (59.6%)
165 (62.9%)
245
262
0.490
Age group
(in months)
06-12
>12-24
>24-36
>36-48
>48-60
>60
16 (42.1%)
20 (23.8%)
27 (29.7%)
33 (33.3%)
47 (49.5%)
53 (53.0%)
22 (57.9%)
64 (76.2%)
64 (70.3%)
66 (66.7%)
48 (50.5%)
47 (47.0%)
38
84
91
99
95
100
<0.001
Maternal educational 
level
≤9th grade
9th – 12th grade
> High school
No data
50 (42.7%)
58 (38.6%)
85 (37.8%)
67 (57.3%)
93 (61.6%)
140 (62.2%)
117
151
225
14
0.656
No. of siblings ≤6 
years of age
0
1
2
139 (37.1%)
54 (37.9%)
3 (37.5%)
220 (62.9%)
86 (61.4%)
5 (62.5%)
359
140
8
0.997
Living with a smoker No
Yes
No data
144 (41.1%)
49 (32.5%)
206 (58.9%)
102 (67.5%)
350
151
6
0.083
Antibiotic use in the 
preceding month 
No
Yes
147 (38.6%)
49 (38.8%)
234 (61.4%)
77 (61.1%)
381
126
0.965
Vaccine (PCV7) Unvaccinated
≥1 dose
45 (38.1%)
151 (38.8%)
73 (61.9%)
238 (61.2%)
118
389
0.980
Vaccination status Unvaccinated
Partially vaccinated
Age-appropriately vaccinated
45 (38.1%)
24 (38.1%)
127 (39.0%)
73 (61.9%)
39 (61.9%)
199 (61.0%)
118
63
326
0.983
Pn
e
u
m
o
co
cc
a
l c
o
lo
n
iza
tio
n
 
in
 
Co
im
br
a
 
78 
Table 2. Vaccination status by number of doses of 7-valent pneumococcal 
conjugate vaccine received 
No. of 
doses of 
PCV7 
Vaccination status 
Total Unvaccinated Partially 
vaccinated 
Age 
appropriately 
vaccinated 
0 
1 
2 
3 
4 
118 
0 
0 
0 
0 
0 
18 
13 
31 
0 
0 
4 
28 
86 
209 
118 
22 
41 
117 
209 
Total 118 62 327 507 
 
Pneumococcal colonization status was not associated with maternal education, 
number of siblings below six years of age, living with a smoker, or use of 
antibiotics in the previous month (Table 1). Pneumococcal colonization per se was 
also not associated with vaccination status no matter the criteria used to classify 
vaccination with PCV7: number of doses (P=0.510); one or more doses (P=0.980, 
Table 1); vaccination status (P=0.983, Table 1). 
 
Logistic regression analysis showed that being colonized with S. pneumoniae 
depended on children’s age (as described before) and the number of children 
attending each DCC; the likelihood of being colonized increased with the number 
of children attending each DCC (P=0.038). 
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Fig. 2. S. pneumoniae colonization according to age group 
 
 
Serotype distribution  
The serotype distribution is shown in Table 3. Of the 315 isolates (311 carriers of 
which four had two strains of pneumococci), ten were lost. Thus, the information 
on specific serotype was available for 305 isolates. Among these, 63 (20.7%) were 
VT, 216 (70.8%) NVT and the remaining 26 (8.5%) were NT. Serotypes 19F, 6B 
and 14 were the most prevalent among VTs. Several NVT (23 types) were isolated 
being the most prevalent (in decreasing order) 23A, 16F, 23B, 19A, 21, 17F, 35F, 
11A, and 6A (Table 3). 
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Table 3. Serotype distribution of S. pneumoniae isolates according to the vaccination status 
 
a305 isolates from 301 children (2 different serotypes were isolated in 4 children)
Serotype
Unvaccinated children
(n = 71)
Vaccinated children
(≥1 doses PCV7; n = 234)
Totala
(n = 305)
VaccineTypes (VT)
19F
6B
14
23F
12
11
8
0
20
8
3
1
32
19
11
1
Total VT 31 (43.7%) 32 (13.7%) 63 (20.7%)
Non-Vaccine Types (NVT)
23A
16F
23B
19A
21
17F
35F
11A
6A
10A
24F
15A
38
1
29
15B/C
16A
15F
18A
34
3
7F
9L
5
2
4
3
1
4
1
1
4
2
0
1
0
1
0
2
1
0
1
0
0
0
0
30
20
16
15
16
12
13
11
8
6
8
5
6
4
4
2
2
1
0
1
1
1
1
35
22
20
18
17
16
14
12
12
8
8
6
6
5
4
4
3
1
1
1
1
1
1
TotalNVT 33 (46.5%) 183 (78.2%) 216 (70.8%)
Non-typeable 7 (9.9%) 19 (8.1%) 26 (8.5%)
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Although colonization per se was not associated with vaccination status, the 
distribution of serotypes among vaccinated and unvaccinated children was 
different (Table 3). While prevalence of NVT (46.5%) and VT (43.7%) was similar 
among unvaccinated, NVT were clearly predominant (78.2%) among children with 
≥1 doses of PCV7 (P<0.0001).The proportions of VT and NVT were also 
associated with age group (P<0.0001) as the proportion of NVT which increased 
to maximum levels among age groups “>12-24” and “>24-36” months of age and 
then decreased gradually to the minimum among the eldest (Figure 2). 
 
Antibiotic resistance 
The antibiotic resistance profile of serotyped pneumococci is show on Table 4. Of 
all isolates, 14.4% strains had a penicillin MIC ranging from 0.12 to 1 µg/ml and 
1.3% had a MIC of 2 µg/ml; 7.2% of the strains had a cefotaxime MIC of 1 µg/ml 
and 0.7 had a MIC of 2 µg/ml (Table 4). Other rates of resistance were 20.5% to 
erythromycin, 17.4% to clindamycin, 15.0% to tetracycline, 10.2% to SXT, and 
1.3% to chloramphenicol. All pneumococci were susceptible to levofloxacin and 
vancomycin. For any studied antibiotic on Table 4, the proportions of resistant 
strains were significantly higher among VT (p <0.0001). 
 
Significantly higher proportions of decreased susceptibility to penicillin, and 
resistance to tetracycline were observed among strains from unvaccinated, when 
compared to vaccinated children (Table 4). Nevertheless, when the confounding 
effect by VT strain was controlled through stratification of vaccination status, the 
apparent association between vaccination status and resistance to antibiotics was 
no longer observed.  
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Table 4. Resistant Streptococcus pneumoniae according to serotype and vaccination status 
*
≥1doses of Prevenar; Oral penicillin V: PenicillinI 0.12≤MIC<1 µg/mL, PenicillinR MIC≥2 µg/mL; Penicillin 
parenteral meningitis: PenicillinR MIC≥0.12 µg/mL; Penicillin parenteral nonmeningitis: PenicillinI MIC=4 µg/mL; 
Cefotaxime (meningitis): CefotaximeI MIC=1.0µg/mL, CefotaximeR MIC≥2.0µg/mL; Cefotaxime (nonmeningitis): 
CefotaximeI MIC=2.0µg/mL; SXT, sulfamethoxazole-trimethoprim; n.d., not done (small number of isolates); 
MIC, minimum inhibitory concentration. 
 
 
Of note, serotype 19F, a VT, was the second most frequently isolated serotype 
(being 23A the most frequent one). Six out of 32 children with 19F were <2 years 
of age, 22/32 (69%) had received at least one dose of PCV7 and 18/32 (56%) 
were age-appropriately vaccinated. Of 32 serotype 19F isolates, 46.9% had 
decreased susceptibility to penicillin (intermediate and high-level penicillin 
resistance were found in 15.7% and 31.2% of the strains, respectively). The rates 
of resistance to other antimicrobial agents were: 40.6% to cefotaxime, 90.6% to 
erythromycin, clindamycin and tetracycline. All were susceptible to 
chloramphenicol, levofloxacin and vancomycin.  
 
Among NVT, penicillin non-susceptibility and resistance to macrolides was more 
frequent among serotypes 19A, 15A and 6A. For serotype 19A (n=18), penicillin 
non-susceptibility was 33%, resistance to macrolides and to clindamycin was 
55.6% and to cefotaxime was 27.8%. 
Antibiotic
All 
isolates 
n=305
no. (%)
Type Vaccination status
Non-VT
n=216
no. (%)
Non-typeable
n=26
no. (%)
VT
n=63
no. (%) p-value
Unvaccinated
n= 71
no. (%)
Vaccinated*
n = 234
no. (%) p-value
Oral penicillin V
PenicillinI
PenicillinR
44 (14.4)
4 (1.3)
17 (7.9)
0
3 (11.5)
0
24 (38.1)
4 (6.3)
<0.0001
n.d.
16 (22.5)
2 (2.8)
28 (12.0)
2 (0.9)
0.026
n.d.
Penicillin parenteral (meningitis) 48 (15.7) 17 (7.9) 3 (11.5) 28 (44.4) <0.0001 18 (25.4) 30 (12.8) 0.011
Penicillin parenteral (nonmeningitis) 0 0 0 0 - 0 0 -
Cefotaxime (meningitis)
CefotaximeI
CefotaximeR
22 (7.2)
2 (0.7)
5 (2.3)
0
1 (3.8)
0
16 (25.4)
2 (3.2)
<0.0001
n.d.
10 (14.1)
2 (2.8)
12 (5.1)
0
0.011
n.d.
CefotaximeI (nonmeningitis) 2 (0.7) 0 0 2 (3.2) n.d. 2 (2.8) 0 n.d.
SXT 31 (10.2) 12 (5.5) 5 (19.2) 14 (22.2) <0.0001 13 (18.3) 18 (7.7) 0.035
Chloramphenicol 4 (1.3) 4 (1.9) 0 0 n.d. 0 4 (1.7) n.d.
Erythromycin 48 (20.5) 25 (11.6) 5 (19.2) 37 (58.7) <0.0001 19 (26.8) 50 (21.3) 0.341
Clindamycin 40 (17.4) 20 (9.3) 2 (7.7) 35 (55.6) <0.0001 17 (23.6) 41 (17.4) 0.227
Tetracycline 35 (15.0) 15 (6.9) 3 (11.5) 35 (55.6) <0.0001 18 (25.4) 36 (15.3) 0.054
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Clonal analysis of drug-resistant strains 
DNA fingerprinting through PFGE was performed for all 86 drug-resistant isolates 
which included 13 serotypes and 7 NT strains (Table 5).  Twenty-four clones were 
identified, six associated with specific VT, 15 associated with specific NVT, and 
three associated with both VT and NVT. Among the latter, two clones had isolates 
of serotypes 19A and 19F and one had isolates expressing serotypes 14, 15A, 
19A, and 19F. Fifteen clones were represented by unique isolates and the 
remaining were represented by two to 31 isolates. The largest clone, 19F/19A-1, 
included 26 of the 30 drug resistant serotype 19F isolates and five of the 13 drug-
resistant 19A isolates. This clone was isolated from 6 day-care centers. 
 
Clonal diversity was higher among drug resistant NVT strains than among drug-
resistant VT strains: SID for NVT was 0.92 (95% CI, 0.89-0.96) compared to 0.68 
(95% CI, 0.54-0.82) for VT. There was a low association between drug-resistant 
clones and individual DCCs as the AR was only 0.17 for NVT strains and 0.13 for 
VT strains. 
 
 
Pn
e
u
m
o
co
cc
a
l c
o
lo
n
iza
tio
n
 
in
 
Co
im
br
a
 
84 
Table 5. Clonal distribution of all antibiotic-resistant strains 
 
Ery – erythromycin; Da – clindamycin; Tet – tetracycline; Chl – chloramphenicol; SXT - 
sulfamethoxazole-trimethoprim; PenicillinI 0.12≤MIC<1 µg/mL; PenicillinR MIC≥2 µg/mL; aPFGE was 
done for antimicrobial-resistant isolates; bPFGE clones were named by using a combination of 
serotype(s) found within the clone followed by an arbitrary sequential number.  
 
 
Serotype
No. of isolates with 
PFGE donea
PFGE clonesb Resistance profile
Day-care centers
(no. of isolates)
Vaccine types
6B 4/19 6B-1 (1)
6B-2 (3)
IP, Ery, Da, Tet
IP, SXT
A (1)
C (3)
14 11/11 14-1 (3)
14-2 (3)
15A/14/19F/19A-1 (5)
P (1), IP, SXT
Ery (2); Tet, SXT
IP, Tet (4), Ery, Da, SXT (4)
A (2); H (1)
E (1); F (2)
B (3); C (1); F (1)
19F 30/32 19F/19A-1 (26)
15A/14/19F/19A-1 (2)
19F/19A-2 (1)
19F-3 (1)
IP(1), P(2),Tet, Ery, Da
IP, Tet, Ery, Da
IP, Tet, Ery, Da, SXT
P, SXT
A (9); B (10); C (3); D (2); E (2)
B (2)
H (1)
F (1)
23F 1/1 23F-1 (1) IP C (1)
Nonvaccine types
6A 4/12 6A-1 (1)
6A-2 (3)
IP, Tet, Ery, Da
IP, Tet, Ery, Da
H (1)
H (3)
11A 5/12 11A-1 (3)
11A-2 (2)
IP (1), Ery, Da (2), ISXT (1)
Ery, SXT
A (1); B (2)
A (2)
15A 5/6 15A/14/19F/19A-1 (5) IP, Ery, Da A (3); C (1); D (1)
15B/C 1/4 15B/C-1 (1) Ery, SXT A (1)
17F 1/16 17F-1 (1) Tet C (1)
18A 1/1 18A-1 (1) IP B (1)
19A 13/18 19F/19A-1 (5)
15A/14/19F/19A-1 (1)
19F/19A-2 (5)
19A-3 (2)
Ery, Da, Tet, Chl
P, Tet, Ery, Da
IP, Tet, Ery, Da, ISXT
ISXT, RSXT
B (2); G (3)
A (1)
A (4); H (1)
B (1); C (1)
21 1/17 21-1 (1) SXT G (1)
29 1/4 29-1 (1) Ery E (1)
NT 7/26 NT-1 (3)
NT-2 (1)
NT-3 (1)
NT-4 (1)
NT-5 (1)
Tet (2), Ery, Da (2), SXT(1)
P
IP, SXT
Ery, Da
IP, Tet, Ery, SXT
D (1); H (2)
C (1)
C (1)
C (1)
C (1)
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DISCUSSION 
 
This is the first study of NP pneumococcal carriage undertaken among healthy 
children attending DCC in the central region of Portugal. Although similar studies 
have been conducted for over a decade in the Oeiras and Lisbon area, the 
epidemiology of colonization in other regions of the country has not been studied. 
Thus it is unclear whether features consistently found in Oeiras and Lisbon are 
representative of the country.  
 
Several parallels can be drawn between the findings of this study and those 
conducted in Oeiras (i) the high prevalence (61.7%) of S. pneumoniae NP carriage 
was similar to that reported in Oeiras (14, 29, 36), but above those observed in 
other countries after the introduction of PCV7, such as Greece (18) and Canada 
(22); (ii) relatively high rates of drug resistance were found, with 29% of the 
isolates being resistant to at least one antibiotic, a finding comparable to what has 
been found in Oeiras (26, 29, 40); (iii) in this study we found very high PCV7 
uptake among children attending DCC in Coimbra (76.7% had received at least 
one dose), consistent with reports from Oeiras (37).  
 
Of interest, colonization proportions were found to vary with the number of children 
attending each DCC and with age but not with vaccination status or other studied 
factors. The association between S. pneumoniae colonization and the number of 
children in each DCC found in our study is consistent with the finding that DCC 
play a key role in the pneumococcal carriage rate of its attendees and even on the 
levels of carriage in the community where they are located (19). The association 
between colonization and age group has also been reported (3). In our study, 
colonization was not associated with level of the mother’s education, number of 
siblings below six years of age, living with a smoker or previous use of antibiotics, 
factors which have been associated with increased carriage of pneumococci (13, 
22). 
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Consistent with other studies NP carriage was not associated with PCV7 
vaccination status. However, while prevalence of NVT and VT was similar among 
unvaccinated, NVT were clearly predominant among vaccinated children 
(P<0.0001), that had significantly lower prevalence of VT. Although we have no 
pre-vaccination data to compare with, our findings are consistent with those 
reported by others (14, 15, 18, 20, 27, 28, 32), with reduction of VT strains and 
increase in NVT (serotype replacement) among vaccinated children. 
In our study, VT serotypes 4, 9V and 18C were not identified and the most 
prevalent VT serotype were 6B, 14 and 19F, which accounted for approximately 
20% of the isolates. Of note, despite widespread use of PCV7, 19F was the 
second most frequently isolated serotype. Grivea et al. (18) on their observational 
study about the impact of PCV7 in DCCs in Central Greece reported a substantial 
reduction of colonization for VT 6B, 14 and 23F; serotype 19F decreased but the 
decline did not reach a statistically significant level. Of interest, a recent study 
aimed to estimate the vaccine efficacy against acquisition of pneumococcal 
carriage using previously published trial data found no statistically significant 
efficacy of PCV7 against vaccine serotypes 19F and 14 (35a). In the present 
study, 9.1% of the pneumococci isolates were NT. In other studies, including the 
ones conducted in Oeiras, comparable proportions were found (18, 38). 
 
In this study the clonal diversity among drug-resistant NVT strains was significantly 
higher than among drug-resistant VT strains a finding that warrants continuous 
surveillance as NVT are increasingly abundant. Three clones were identified that 
expressed more than one serotype. The same clones expressing these various 
serotypes were detected in a previous study conducted in Oeiras between 2001-
2003 an observation that suggests that capsular switch events that led to the 
circulation of these isolates sharing a common molecular type but expressing 
different capsular types occurred at least a few years ago (26). 
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In conclusion, rates of vaccination and NP carriage are high in DCCs in the central 
region of Portugal and most children are colonized with NVT. While prevalence of 
NVT and VT was similar among unvaccinated, NVT were clearly predominant 
among vaccinated children. Although we have no pre-vaccination data from this 
region of Portugal to compare with, our findings are consistent with those reported 
by others showing reduction of colonization by VT after vaccination and 
replacement by NVT. The proportion of resistant pneumococci was significantly 
higher among unvaccinated children and among VT. Relatively high rates of drug 
resistance were found. This study is a platform for future surveillance activities. 
Ongoing surveillance is critical, because changes in the resistance patterns 
among NVT can occur with time.  
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Antibiotic consumption remains a main 
driving force of antimicrobial resistance in 
the era of pneumococcal conjugate vaccines  
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Abstract 
 
We compared colonization patterns between two areas: Montemor-o-Novo, a 
rural area, and Oeiras, an urban area. Between January-March of 2009 and 
2010, 1,088 and 756 nasopharyngeal samples were obtained from children 
attending day care centers in the urban and in the rural area, respectively. 
Socio-demographic and clinical data were also obtained. Pneumococci were 
isolated, serotyped and antibiotyped. We used multiple logistic regression to 
evaluate association between carriage, socio-demographic and clinical 
variables. Carriage (c.a. 61%) and PCV7 use (complete schedule, c.a. 70%) 
were comparable in both areas. In the urban area there were higher rates of 
antimicrobial resistance (32.4% vs 21.6%, p<0.001) and higher rates of 
antimicrobial consumption in the month preceding sampling (16.6% vs 11.6%, 
p=0.004). Antimicrobial consumption during the last month (OR=2.58, 95%CI: 
1.61-4.17), being colonized with serotype 19A (OR=3.52, 95%CI: 1.79-6.91) or 
a NT strain (OR=11.33, 95%CI: 5.36-23.96) and attending day care in the urban 
area and simultaneously being colonized with 19A (OR=2.49, 95%CI: 1.07-5.81) 
were the variables that better explained the differences in antibiotic resistance 
between the two areas. This study shows that despite the widespread use of 
PCV in Portugal, antibiotic consumption remains a driving force for maintenance 
of antimicrobial resistant pneumococci in the community. 
 
 
Introduction 
 
Streptococcus pneumoniae is one of the major pathogens implicated in pediatric 
infections that can range from acute otitis media to more severe conditions such 
as bacteremia and meningitis. S. pneumoniae is also a frequent colonizer of the 
human nasopharynx. Since nasopharyngeal carriage is particularly common in 
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pre-school children (1) and colonization precedes disease (8) it is very important 
to monitor the epidemiology of pneumococci in this age group.  
 
Our group carried out pneumococcal colonization studies since 1996 in day care 
centers (DCC) in the Lisbon area (2, 6, 11, 13, 20). Recently, we described the 
impact of the 7-pneumococcal conjugate vaccine (PCV7) in pneumococcal 
colonization in this particular population (18, 21) and also in Coimbra, a city in 
the central region of the country (17).  
 
The study presented here was conducted in a rural area, in the southern part of 
Portugal, Montemor-o-Novo. The results were compared to the ones obtained in 
Oeiras (a suburb of Lisbon). 
 
 
Methods 
 
Study population 
Nasopharyngeal samples were collected from DCC attendees up to 6 years old 
living in Oeiras or Montemor-o-Novo. Oeiras is a village and a municipality in 
western Lisbon metropolitan area, with 168,475 inhabitants. It is one of the most 
populous municipalities in Portugal, with a density of 3,687/km2 distributed 
through ten civil parishes in a total area of 45.7km2. Montemor-o-Novo is a city 
and municipality in the southern region and is one of the largest municipalities of 
Portugal with a total area of 1232.10km2, but with a low population density of 
about 15/km2. The majority of the population (12,000 of 18,540 inhabitants) lives 
in the city that includes 2 out of 10 civil parishes. In Oeiras we invited 9 DCC to 
participate in the study, while in Montemor-o-Novo all DCC were invited (n=16) 
in order to have a comparable number of children in the two regions. The 
number of attendees in each DCC varied between 25 and 174 in Oeiras and 
between 7 and 104 in Montemor-o-Novo. At time of this study, PCV7 and 
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PCV10 were not included in the National Vaccination Program neither subsided 
by the state but were available in the Portuguese market since June 2001 and 
April 2009, respectively. PCV13 replaced PCV7 in January of 2010.  
 
Questionnaire and pneumococcal isolation  
In the winter months of January - March of 2009 and 2010 one nasopharyngeal 
swab was taken from each child, whose parents or guardians had signed 
informed consent, as described in our previous studies (19). Additionally, 
information about age, gender, antibiotic consumption, recent disease, and 
pneumococcal and flu vaccinations was obtained through questionnaires. 
Pneumococcal identification was done by routine procedures (20), based on 
colony morphology on blood agar plates, optochin susceptibility and bile 
solubility. All strains were stored at -80ºC. In both regions the same specialized 
nurses did sampling; pneumococcal isolation was performed in our laboratory.  
 
Interpretation of vaccination status 
The classification “complete”, “complete to age” and “incomplete” was done as 
previously described by Sá-Leão (18). Vaccination was considered “complete” 
if, at the time of sampling, it was done according to one of the following 
schemes: 4 doses, if starting vaccination at 2 months of age; 3 doses, if starting 
vaccination at 7-11 months of age; 2 doses, if starting vaccination at 12-24 
months of age and 1 dose if starting vaccination at ≥ 24 months. Vaccination 
was considered “complete to age” if at the time of sampling the child had 
received all recommended doses, according to the age at initiation of 
vaccination. Vaccination was considered “incomplete” if at time of sampling the 
child had not received all recommended doses according to the age at initiation 
of vaccination. 
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Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed using the Kirby-Bauer 
technique, according to the Clinical and Laboratory Standards Institute (CLSI) 
recommendations and definitions (4). The antimicrobial agents tested were 
chloramphenicol, erythromycin, clindamycin, tetracycline, and 
sulfamethoxazole-trimethoprim (SXT). Antibiotic disks were purchased from 
Oxoid (Hampshire, England). MICs for penicillin, ceftriaxone and amoxicillin 
were performed by E-test (AB Biodisk, Solna, Sweden) according to the 
manufacturer’s recommendations. In the interpretation of decreased penicillin 
susceptibility, isolates were divided into intermediately resistant (0.1 µg/ml ≤ 
MIC ˂ 1.5 µg/ml) and resistant (MIC ≥ 1.5 µg/ml), according to CLSI guidelines 
for oral penicillin V (4).  
 
Capsular typing  
Serotyping was carried out for all pneumococcal isolates by a combination of 
multiplex PCRs using the primers previously described by Pai et al. (14) or by 
CDC (www.cdc.gov). The isolates that could not be typed by this method were 
serotyped by Quellung reaction using specific antisera (Statens Serum Institute, 
Copenhagen, Denmark) (23). Non-typeable strains (NT) were defined by the 
absence of cpsA gene and a negative reaction with Omniserum (Statens Serum 
Institute, Copenhagen, Denmark). 
 
Statistical analysis 
Differences between Montemor-o-Novo and Oeiras were tested using a two 
tailed t-test or a two tailed Wilcoxon test to compare means and the Fisher exact 
test to compare percentages (25). A p-value of 0.05 was used as a threshold to 
decide which variables were significantly associated with differences between 
the urban (Oeiras) and the rural (Montemor-o-Novo) regions. A modified 
Simpson’s index of diversity was used to analyze serotype diversity (3). For the 
multiple regression logistic analysis a backward stepwise regression was used 
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to choose the most parsimonious model, that is, the one with the lowest Akaike 
information criterion (AIC) and the lowest number of independent variables. The 
model was further inspected for multicollinearity and the goodness of fit was 
checked (7). For each variable odds ratio (OR) were estimated as well as the 
corresponding confidence interval at 95%. A variable whose OR confidence 
interval did not contain 1 was considered statistically significant. Accordingly, an 
OR lower than 1 was considered a protective factor and an OR higher than 1 
was considered a risk factor. 
 
 
Results 
 
Population characterization 
A total of 1,848 children were enrolled in this study, 1,092 from Oeiras and 756 
from Montemor-o-Novo (Table 1). About 53% of these children were enrolled 
during 2009 and 48% were female. The mean number of children in each DCC 
in the two regions was significantly different (p-value <0.001). The mean age of 
the children enrolled was lower in Oeiras (3.6 vs 3.2, p<0.001). 
 
During this study 79.5% of the children had taken at least one dose of 
pneumococcal conjugate vaccine, however only 1.1% had taken PCV10 and 
none had taken the PCV13. A high percentage of children in Montemor-o-Novo 
had taken at least one dose of pneumococcal vaccine (83.2% vs 76.4%) (Table 
1). There was, nonetheless, a difference in the vaccination status in the two 
regions. The proportion of unvaccinated children in Oeiras (23.1%) was 
significantly higher (p=0.001) than in Montemor-o-Novo (16.7%). On the other 
hand, the number of incomplete doses was higher among children in Montemor-
o-Novo (Table 1). No difference between the regions was noticed regarding the 
vaccination against seasonal influenza and H1N1 (Table 1). 
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Table 1 – Demographic data 
 
Bold, statistically significant; NA, not available; athe majority of children took only PCV7. 
Nine children (5 in Oeiras and 4 in Montemor-o-Novo) took also one dose of PCV10 and 
4 children in each region took only PCV10; bin this group children with 4 doses of 
vaccine are included; conly asked in 2010; donly available in 2010 
 
The consumption of antibiotics among children in the two regions was not 
statistically different at the time of sampling, but it was significantly higher in 
Oeiras during the preceding month and this difference was even more clear with 
recurrent use of antibiotics (three or more courses in the last 6 months) (Table 
1). Amoxicillin and the association between amoxicillin and clavulanic acid were 
the antibiotics more frequently used in these populations and otitis and throat 
infections were the major causes for antibiotherapy (data not shown). 
 
Total Urban area Rural area p-value
Population (< 7 years) 1848 1092 756
Average number of children 94.4±50.7 36.1±30.7 <0.001
Mean age (years) 3.2±1.5 3.6±1.5 <0.001
Gender (female) 958 48.3% (525/1088) 47.7% (361/756) 0.84
Pneumococcal vaccinea N=1069 N=720
unvaccinated 367 23.1% (247) 16.7% (120) <0.001
at least one dose 1422 76.9% (822) 83.2% (600) 0.001
4 doses 986 52.1% (557) 59.6% (429) 0.002
complete to ageb 1227 67.7% (724) 69.9% (503) 0.35
incomplete 195 9.2% (98) 13.5% (97) 0.004
NA 59 23 36
Flu vaccinec 45 7.2% (15/422) 4.6% (30/331) 0.164
H1N1d 102 10.2% (49/481) 14.1% (53/376) 0.109
Antibiotic consumption
at sampling 62 3.8% (41/1065) 2.8% (21/743) 0.293
during last month 255 16.6% (172/1034) 11.6% (83/713) 0.004
6 months before (≥3 courses) 546 41.3% (406/983) 19.6% (140/713) <0.001
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Pneumococcal carriage and serotype distribution 
The prevalence of colonization was not different in the two regions, being c. a. 
60% (Table 2). A significant difference in the prevalence of antibiotic resistant 
strains was observed between the urban and rural region, with a higher 
prevalence in Oeiras (32.4% vs 21.6%) (Table 2). The highest rate of resistance 
was found for macrolides 21.6%; 19.8% of the isolates were resistant to three or 
more antimicrobial agents. 
 
Tabela 2 - Pneumococcal colonization and antibiotic resistance 
 
Penicillin I, 0.1≤MIC<2µg/mL; Penicillin R, MIC≥2µg/mL; MDR, multidrug resistant- 
resistant to 3 or more antimicrobial agents; bold, statistically significant 
 
A total of 1,129 pneumococcal isolates were serotyped and 46 serotypes plus 
non-typeable strains were recovered. In particular, the 454 pneumococcal 
isolates from Montemor-o-Novo belonged to 34 serotypes, and the 675 
pneumococcal isolates from Oeiras belonged to 39 serotypes (Figure 1). 
Diversity, as estimated by the modified Simpson’s index of diversity, was higher 
in Montemor-o-Novo (0.95, CI 95% 0.942-0.955) than in Oeiras (0.928, CI 95% 
0.92-0.934). Furthermore, the rank of the serotypes was also different in both 
regions. In Montemor-o-Novo, the most prevalent serotypes were 19A (11%), 
Characteristic Urban area Rural area p-value
Colonization (yes) 61.8% (675/1091) 60.0% (454/756) 0.467
Antibiotic resistance (yes) 32.4% (219) 21.6% (98) <0.001
Macrolides 25.9% (175) 15.1% (69) <0.001 
Penicillin (R) 2.4% (16) 1.5% (7) 0.395 
Penicillin (I) 19.4% (131) 10.1% (46) <0.001 
MDR 24.1% (163) 13.2% (60) <0.001 
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11A (8.8%) and NT (8.6%) whereas in Oeiras the most prevalent serotypes 
were 19A (13.9%), 6C (12.4%) and 3 (9.9%) (Figure 1). Potential coverage of 
the PCV10 and PCV13 were 9% and 35%, respectively, in Oeiras. In Montemor-
o-Novo corresponding figures were 9% and 27%. 
 
 
Figure 1 – Serotype and antibiotype distribution in Montemor-o-Novo (A) and in Oeiras 
(B). 
 
Antibiotic resistance and serotypes 
Figure 1 shows the distribution of the major serotypes in the two regions. In the 
majority of cases resistance to β-lactam and macrolides was associated with the 
PCV7
PCV10
PCV13
PCV7
PCV10
PCV13
Susceptible to all antibiotics
Erythromycin resistant (REry)
Penicillin non-susceptible (NSPG)
NSPG + REry
Other resistance patterns
A
B
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same serotypes in both regions (19A, 15A and NT strains), with the exception of 
serotype 6C, that was associated with this type of resistance in Oeiras, only. 
 
Multiple logistic regression: pneumococcal colonization 
Based on the differences found in the previous exploratory analysis we adjusted 
a model to explain pneumococcal colonization considering the number of 
children in each DCC, pneumococcal vaccination status, geographic region, and 
antibiotic consumption as independent variables. The final model included the 
variables in which we observed a significant difference in the univariate 
analysis: region, age, antibiotic consumption during the last month and the 
recurrent use of antibiotics in the last six months. Additionally, we tested for one 
interaction term between children age and antibiotic consumption during the last 
month. Only age and antibiotic consumption during the last month were 
statistically associated with pneumococcal colonization (Table 3). Children that 
took antibiotic during the last month had 73% (OR=0.27, 95%CI: 0.13-0.52) less 
probability of being colonized than children that did not. Being older decreased 
the odds to be colonized with pneumococci, in average the decreased was 
about 1.8% in prevalence for each year of age. 
 
Multiple logistic regression: pneumococcal resistant strains 
Concerning the proportion of resistant isolates and taking into account the 
results obtained after data exploration we adjusted a multiple logistic model to 
explain the proportion of resistant isolates colonizing children, considering the 
region, antibiotic consumption, class of antibiotic, age, vaccine status and the 
pneumococcal serotypes in which the observed number of resistant isolates 
was significantly different from the one estimated - 19A and NT. We also tested 
two interactions terms region and serotype, and serotype and antibiotic 
consumption during last month. The final model included region, serotype, 
antibiotic consumption during the last month and an interaction term between 
region and serotype. In the model, only serotype, antibiotic consumption during 
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the last month and the interaction term between region and serotypes explained 
the differences in the prevalence of resistance between the two regions (Table 
4). Antibiotic consumption during the last month increased the odds to be 
colonized by resistant pneumococcal strains in 2.5 fold (OR=2.58, 95%CI: 1.61-
4.17). Colonization by serotype 19A and NT strains increased the odds to be 
colonized by resistant pneumococcal strain in 3.5 (OR=3.52, 95%CI: 1.79-6.91) 
and 11.3 (OR=11.33, 95%CI: 5.36-23.96), respectively. The odds of a child to 
be colonized with a resistant strain of 19A serotype was 2.5 higher (OR=2.49, 
95%CI: 1.07-5.81) in children attending DCC in Oeiras compare to Montemor-o-
Novo. 
 
Table 3 - Odds ratio and confidence intervals estimated from logistic model to 
explain pneumococcal colonization  
 
Bold, statistically significant  
 
 
VARIABLE
unadjusted
OR
adjusted
OR
CI 95% p-value
Region
Montemor-o-Novo
Oeiras
1
1.02
1
1.18 0.95 – 1.45 0.131
Antibiotic consumption:
during last month (yes)
6 months before sampling (yes)
0.54
0.89
0.27
0.81
0.13 – 0.52
0.64 – 1.01
<0.001
0.066
Age 0.95 0.92 0.86 – 0.99 0.045
Age x antibiotic consumption 
during the last month
0.99 1.01 0.83 – 1.23 0.900
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Table 4 - Odds ratio and confidence intervals estimated from logistic model to 
explain the colonization with resistant pneumococcal strains 
 
Bold, statistically significant; NT, nontypeable 
 
 
Discussion 
 
Several papers have described risk factors for pneumococcal colonization (1, 5, 
9, 10, 12, 16, 22), and the majority are consensual in the fact that major risk 
factors can change from country to country or from region to region depending 
on several factors (10, 24). 
 
VARIABLE 
unadjusted 
OR 
adjusted 
OR 
CI 95% p-value 
Region 
Montemor-o-Novo (rural) 
Oeiras (urban) 1.50 
1 
1.81 0.85 – 2.10 0.208 
Antibiotic consumption: 
during last month (yes) 2.58 1.61 – 4.17 <0.001
Serotype
Other
19A
NT 
1
2.56
2.79 
1
3.52
11.33 
1.79 – 6.91
5.36 – 23.96 
<0.001
<0.001 
Serotype x Region
19A x Montemor-o-Novo
19A x Oeiras
NT x Montemor-o-Novo
NT x Oeiras
1
1.97
1
1.03 
1
2.49
1
0.66 
1.07 – 5.81
0.24 – 1.82
0.034
0.429 
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In this study we compared the prevalence of pneumococcal colonization and the 
prevalence of antibiotic resistant pneumococcal strains in urban and rural area 
of Portugal.  
 
We observed that although the pneumococcal carriage was similar, the serotype 
diversity and the prevalence of resistant strains were different. We tried to 
investigate the variables that could account for this difference. We accessed for 
differences among the demographic data in the two areas and we observed that 
the mean age of children from Montemor-o-Novo was significantly higher. Also, 
on average, the number of children per DCC unit was higher in the urban area. 
Antibiotic consumption during the last month and the recurrent use of antibiotics 
were also significantly higher in Oeiras. The proportion of unvaccinated children 
in Oeiras was also significantly higher; however the proportion of children with 
incomplete vaccination was higher in Montemor-o-Novo. However, all these 
variables were not significant in the multiple logistic regression models that were 
constructed to explain pneumococcal colonization in general and carriage of 
resistant strains, in particular. 
 
The colonization model showed that only previous antibiotic consumption and 
being older were protective factors for pneumococcal colonization. In a previous 
study conducted in Italy, where the colonization rates were compared between a 
rural and urban area, the authors mention that living in a rural area significantly 
decreased the odds of carrying nasopharyngeal respiratory pathogens (15). 
This difference in the conclusions reached by the two studies could be attributed 
to the differences between regions.  
 
When we performed the multivariable analysis to explain the difference in the 
resistance rates in the two regions, we observed that (i) antibiotic consumption 
during the last month, (ii) colonization with pneumococcal serotype 19A or a NT 
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strain, and (iii) attending DCC in Oeiras and being colonized by a resistant 19A 
strain increased the odds of being colonized by pneumococcal resistant strains.  
 
The results obtained in this study led us to conclude that the most important 
factor influencing carriage of resistant pneumococci is antibiotic consumption. 
These results alert, that in the era of widespread use of PCVs antibiotic 
consumption remains a main driving force for maintenance of pneumococcal 
resistant strains in the community. Judicious use of antibiotics remains a priority 
in public health. 
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diversity among elderly living in Portugal. 
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ABSTRACT 
 
Background: While numerous studies have looked at colonization among young 
children, much less is known among the elderly, the other age group for which the 
incidence of pneumococcal disease is high. This study, pioneer in Portugal, aimed 
to evaluate pneumococcal carriage in adults aged over 60 years. 
Methods: Between April and November of 2010, nasopharyngeal and 
oropharyngeal swabs of adults (>60 years), living in Oeiras (n= 651), an urban 
area, or in Montemor-o-Novo (n=647), a rural area, were obtained. Pneumococci 
were identified by standard procedures and by PCR detection of genes cpsA and 
lytA. Isolates were characterized by antibiotype, serotype and MLST. Associations 
between pneumococcal carriage, socio-demographic and clinical factors were 
evaluated using a multiple logistic regression. 
Results: A total of 1,298 adults were enrolled. Only 4.1% were smokers. Fifty-nine 
percent of the participants were vaccinated with the seasonal influenza vaccine 
and only 4.3% with the 23-valent pneumococcal polysaccharide vaccine. Twenty-
nine (2.2%) adults carried bona fide capsulated pneumococci. There were more 
adults carrying pneumococci in the rural area (3.4%) than in the urban area (1.1%) 
(p=0.004). One adult carried two different pneumococcal strains in the 
nasopharynx. The 30 strains expressed 18 capsular types and 22 MLST types. 
Sixteen isolates showed antimicrobial resistance. Smoking increased seven-fold 
the odds for carriage (OR=7.4, CI 95%: 2.56-21.27) whereas living in an urban 
area decreased the odds to colonization by 72% (OR=0.28, CI 95%: 0.11-0.68). 
Conclusion: The prevalence of pneumococcal carriage in the elderly is low and 
serotype and genotype diversity is high. Smoking is an important risk factor for 
colonization whereas living in Oeiras seems to be a protective factor.  
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INTRODUCTION 
 
Streptococcus pneumoniae or pneumococcus remains a leading cause of 
infectious diseases worldwide. The incidence of invasive pneumococcal disease is 
age-dependent being highest at the extremes of age. While the burden of disease 
is substantial, pneumococcus is a commensal that colonizes asymptomatically the 
nasopharynx of humans. Carriage is important as it is a fundamental step for 
infection and for transmission (reviewed in (3)). While, several pneumococcal 
carriage studies have been conducted among young children much less is known 
about the carrier state among the elderly, the other age group where the incidence 
of invasive pneumococcal disease is highest. 
 
One of the main virulence factors of pneumococcus is the capsule and until now, 
more than 90 serotypes have been described (4, 5, 13, 25). Vaccination proved to 
be the best way to decrease infections and in 1983 a pneumococcal 
polysaccharide vaccine, Pneumovax23, was licensed. This polysaccharide 
vaccine was designed preferentially for adults and for children older than 2 years 
old, but its efficacy remains controversial (8, 22). In 2000 another pneumococcal 
vaccine, the seven-valent conjugate vaccine (PCV7) targeting the seven serotypes 
that frequently caused invasive disease in children in USA, was introduced in the 
market. The efficacy of this vaccine on the decline of invasive pneumococcal 
infection (IPD) caused by serotypes covered by PCV7 was reported in several 
countries (2, 9, 11, 14-16). In the USA, the effect of PCV7 was also observed in all 
populations, with a concomitant reduced incidence of IPD in adults (26, 28). 
Recently, we published a study that described the changes that occurred in 
colonization among Portuguese children when c.a. 60% of them had received at 
least one dose of PCV7 (29). In that study we observed a decline of PCV 
serotypes, but carriage and antimicrobial resistance was maintained. In 2010, a 
new pneumococcal conjugate vaccine (PCV13) appeared in the market, potentially 
covering for six additional serotypes: 1, 3, 5, 7F, 6A, and 19A. The effect of this 
*Health care centers are part of the National Health Service and provide primary care, with consultations are on 
general practice and routines; they serve the entire Portuguese population. 
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vaccine in IPD and in pneumococcal colonization has been studied for the past 
two years. In February of 2012 this vaccine was also licensed for adults. 
 
In the current study, conducted in 2010, we aimed to gain insights on 
pneumococcal colonization patterns among elderly and establish a baseline before 
the introduction of the conjugate vaccine in adults with more than 50 years of age. 
 
 
METHODS 
Study design. Between April and November of 2010, adults older than 60 years 
of age, living in Oeiras, an urban area, or in Montemor-o-Novo, a rural area of 
Portugal, were invited to participate in the study. At the time of the study the 10-
valent and 13-valent pneumococcal conjugate vaccines were commercially 
available in the country although they were not part of the national immunization 
plan nor were subsidized by the state. Still the commercial use of the vaccine was 
high with an estimated national coverage of PCV13 in infants in 2010 of 58% 
(Pfizer, personal communication). The municipality of Oeiras has a population of 
over 160,000 inhabitants of which 15% are over 65 years of age, and a population 
density of 3,537/km2. By contrast, the municipality of Montemor-o-Novo has a 
population of 18,500 inhabitants of which 26% are over 65 years of age, and a 
population density of 13/km2. In both areas individuals were enrolled in the local 
health care center* and, in addition, in Montemor-o-Novo retirement homes were 
also visited. Samples were obtained by specialized laboratory technicians (in 
Oeiras) or nurses (in Montemor-o-Novo). The study was registered and approved 
at each health care center. Study participants provided informed written consent 
prior to enrollment. For each adult one nasopharyngeal sample and one 
oropharyngeal sample were obtained. Information about socio-demographic data 
and medical history were obtained through a questionnaire. All samples and 
information were coded upon collection and processed anonymously afterwards. 
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Sampling and isolation. Nasopharyngeal and oropharyngeal samples were 
collected as previously described (30). Swabs were streaked on gentamycin blood 
agar and suspected pneumococcal colonies were isolated and identified following 
routine standard procedures based on optochin susceptibility and bile solubility 
(19, 30). Additionally, isolates showing one or more atypical results in the latter 
assays but displaying a characteristic pneumococcal colony morphology were 
further characterized by the identification of lytA pneumococcal-specific RFLP 
signatures as described by Lull et al. (17). The swabs and the pure cultures were 
frozen and stored at -80ºC in STGG (20). 
 
Capsular typing. Isolates were capsular typed by multiplex PCR using primers 
previously described (23) and www.cdc.gov and/or by the Quellung reaction using 
commercially available pneumococcal antisera (Statens Serum Institute, 
Copenhagen, Denmark) (31). 
 
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was 
performed using the Kirby-Bauer technique, according to the CLSI 
recommendations and definitions (7). The antimicrobial agents tested were 
chloramphenicol, erythromycin, clindamycin, tetracycline, and sulfamethoxazole-
trimethoprim (SXT). Antibiotic disks were purchased from Oxoid (Hampshire, 
England). Interpretation of results followed the CLSI guidelines (7). Isolates were 
also screened for MICs to penicillin and ciprofloxacin with the E-test (AB Biodisk, 
Solna, Sweden) according to the manufacturer’s recommendations. In the 
interpretation of decreased penicillin susceptibility epidemiological breakpoints 
were used: isolates were considered intermediately resistant if the MIC was ≥0.1 
µg/ml and ˂1.5 µg/ml and were considered resistant if the MIC was ≥1.5 µg/ml. 
For ciprofloxacin, strains with MIC≥2 µg/ml were considered resistant. 
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Multilocus sequence typing (MLST). MLST was done essentially as previously 
described (10) using primers with universal M13 tails. Sequencing was conducted 
at Macrogen, Inc. (Seoul, Korea). 
 
Statistical analysis. Socio-demographic and clinical variables were described 
using the mean and standard deviation or percentages as appropriate. Differences 
for each variable, between Oeiras and Montemor-o-Novo, were tested using the 
Student's t-test or the Mann-Whitney U-test for continuous variables and the 
Fisher's exact test to compare proportions (32). Univariate and multiple logistic 
regression analysis were used to assess the goodness of fit of the socio-
demographic and clinical variables to the dependent variable, to be colonized or 
not and, to calculate non- and adjusted odds ratios (OR). A conservative p-value 
<0.1 was used to select the variables in the univariate model to be included in the 
multiple logistic model. For all statistical tests, differences were considered to be 
statistically significant if the p-value < 0.05 or when the adjusted 95% CI odds ratio 
did not include 1.0. Statistical analyses were carried out using R. 
 
 
RESULTS 
Characteristics of the study population. A total of 651 adults over 60 yrs of age 
living in the urban area of Oeiras and 647 living in the rural area of Montemor-o-
Novo participated in the study. Women were slightly overrepresented in both 
populations. The two populations differed significantly in several socio-
demographic and medical characteristics (detailed in Table 1). On average, 
participants from the rural area were older and had less years of formal education. 
Although most participants were retirees, the proportion of those still working was 
significantly lower in the rural area. The household size was comparable in both 
areas but participants from the rural area had significantly less contact with young 
children. On the other hand, in the rural area, participants engaged more  
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TABLE 1. Socio-demographic characteristics and medical history of participants 
atest between levels family household and retirement home; bamong those living at family 
home; csymptoms included runny nose, shortness of breath, sore throat, sputum, cough, 
fever and others; d23-valent pneumococcal polysaccharide vaccine; COPD, chronic 
obstructive pulmonary disease. 
Urban area Rural area p-value
Population (> 60 years) 651 647
Mean age (yrs) 73.07±7.54 75.45±8.19 <0.001
Gender (female) 349 (53.6%) 381 (58.8%) 0.057
Years of school education
0 59 (9.1%) 282 (43.6%) <0.001
1-4
≥ 5
266  (41.0%)
324 (49.9%)
332 (51.3%)
33 (5.1%)
<0.001
<0.001
Retirees 566 (86.9%) 609 (94.1%) <0.001
Housing
family home 649 (99.7%) 532 (82.2%)
retirement home 0 (0.0%) 114 (17.6%) <0.001a
other 2 (0.3%) 1 (0.2%)
Household sizeb 1.44±0.36 1.43±0.39 0.553
Contact with children ≤ 6 yrs
daily at home 26 (4.0%) 13 (2.0%) 0.007
at least once a week 221 (33.9%) 127 (19.6%) <0.001
Recreational activities
at least one activity 119 (18.3%) 340 (52.6%) <0.001
club 69 (10.6%) 88 (13.6%) <0.001
day center 12 (1.8%) 125 (19.3%) <0.001
senior university 16 (2.5%) 3 (0.5%) <0.001
other 19 (2.9%) 10 (1.5%) <0.001
Smoker 38 (5.9%) 15 (2.3%) 0.002
Chronic disease 515 (79.1%) 543 (83.9%) 0.032
COPD 59 (11.6%) 140 (25.8%) <0.001
asthma 18 (3.5%) 55 (10.1%) <0.001
hepatic disease 3 (0.6%) 23 (4.2%) <0.001
renal disease 7 (1.4%) 35 (6.4%) <0.001
Respiratory infection in previous year 219 (33.6%) 365 (56.3%) <0.001
Hospitalization in previous year 95 (14.6%) 93(14.4%) 0.937
Symptoms of respiratory disease at 
samplingc 212 (32.6%) 273 (42.2%) <0.001
Vaccination
seasonal flu 363 (55.8%) 397 (61.4%) 0.043
H1N1 77 (11.8%) 36 (5.6%) <0.001
PPV23d 26 (3.9%) 20 (3.1%) 0.454
Antibiotic consumption
at sampling 17 (2.6%) 10 (1.5%) 0.249
month before 40 (6.1%) 32 (4.9%) 0.396
previous 3 months 70 (10.8%) 44 (6.8%) 0.014
123 
 
frequently in regular recreational activities. Although smoking was not common in 
these populations, the proportion was higher in the urban area (Table 1) with no 
differences (among smokers from the two regions) in the number of smoking years 
and cigarettes per day (data not shown). 
 
Regarding medical history, participants from the rural area were globally less 
healthy. A high prevalence of chronic diseases was reported in both populations 
being higher in the rural area. When individual diseases were analyzed, chronic 
obstructive pulmonary disease (COPD), asthma, hepatic and renal diseases 
remained significantly higher in the rural area. The proportion of participants 
reporting a respiratory infection in the previous year, and current respiratory 
infection symptoms was also higher in the rural area.  
 
Regarding vaccination over half of the participants had received the seasonal flu 
vaccine but significantly less had been vaccinated against H1N1. A tiny proportion 
(<4%) had received PPV23. Antibiotic consumption was low in both regions 
although higher in the urban area. Urinary infections were reported as the main 
reason for taking antibiotics. 
 
Pneumococcal carriage. Of the 1,298 adults, 29 (2.2%) were pneumococcal 
carriers. One adult carried two different isolates. To explore which factors 
contributed to pneumococcal carriage, univariate and multiple logistic regression 
analyses were performed. There were significantly more carriers in the rural area 
than in the urban area (3.4% vs 1.1%, respectively, p=0.004). Carriage was also 
more frequent among smokers (9.4% vs 1.9%, p=0.005), and those with COPD 
(4.5% vs 1.8%, p=0.032). Other variables did not yield statistical significant 
differences. 
The best multiple logistic regression model included the region, smoking and 
having COPD. In the final model, elderly living in the urban area had a lower risk of 
carrying pneumococci, while smokers had an increased risk (Table 2). 
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TABLE 2. Socio-demographic characteristics and medical history of participants  
 
COPD, chronic obstructive pulmonary disease. 
 
Characteristics of pneumococcal isolates. Among the 30 pneumococcal strains 
a high diversity of serotypes and genotypes was detected as 18 serotypes and 22 
sequence types were identified (Table 3). Overall, 23% and 43% of the isolates 
belonged to serotypes included in PCV13 and PPV23, respectively. By MLST, two 
novel sequence types were identified (STs 6987 and 6988 associated with 
serotypes 18A and 23B, respectively). No major lineages were detected and the 
largest group of strains sharing an ST contained three isolates only. Close to half 
of the isolates (46.7%) were resistant to at least one antimicrobial agent; only two 
isolates were multidrug resistant (i.e. resistant to three or more classes of 
antimicrobials) (Table 3). 
 
 
 
 
 
 
 
 
 
Variable Unadjusted OR Adjusted OR(95% CI) p-value
Region
rural 1
urban 0.31 0.28 (0.11 – 0.68) 0.004
Smoking (yes) 5.29 7.38 (2.56 – 21.27) 0.001
COPD (yes) 2.55 2.00 (0.88 – 4.54) 0.111
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TABLE 3. Characterization of the pneumococcal strains 
 IPG, intermediately resistant to penicillin; Ery, erythromycin; Clin, clindamycin; Tet, 
tetracycline; SXT sulfamethoxazole-trimethoprim; Cip, ciprofloxacin 
 
Serotype MLST Resistance pattern Origin No. of isolates
3 180 susceptible rural 2
5 1223 Cip rural 1
6A 1714 Tet, Cip urban 1
6A 460 susceptible urban 1
9L 66 Cip rural 1
11A 62 SXT urban 1
11A 62 Cip urban 1
11A 408 Cip rural 2
15A 63 IPG, Tet urban 1
15B 3097 IPG, Ery, Clin, Tet rural 1
16A 30 susceptible urban 1
18A 6987 susceptible urban 1
19A 276 IPG, Ery, Clin, Tet, Cip rural 1
19A 1201 susceptible rural 1
21 1877 Cip rural 1
22F 433 susceptible rural 3
23A 42 Cip rural 1
23B 6988 susceptible rural 1
23B 439 susceptible rural 2
31 1766 susceptible rural 1
35F 1635 Ery rural 1
35F 1368 susceptible rural 1
36 1635 Ery, Cip rural 1
37 447 Cip rural 2
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DISCUSSION 
 
This is the first study conducted in Portugal aiming to evaluate pneumococcal 
carriage in the elderly population. Previous studies from other countries such as 
Belgium, Israel, and Kenya, described low rates of colonization (typically up to 5%) 
among adults (1, 12, 27). In our study, the pneumococcal carriage rates were also 
low, being higher in the rural area when compared to the urban area (3.4% vs 
1.1%, p=0.004).  
 
Although several differences were noticed among socio-demographic 
characteristics and medical history of the two populations studied, statistical 
analysis identified only two factors that were associated with pneumococcal 
carriage: living in the urban area and being a smoker. While living in Oeiras 
seemed to be a protective effect, decreasing the risk of colonization by 3.5 fold, 
smoking increased the risk of being colonized by seven-fold. Smoking has been 
previously associated with pneumococcal carriage (18). Why living in the urban 
area reduced the risk of carriage is not self-evident. One may hypothesize that 
other important variables to explain this observation were not studied. 
Alternatively, it is conceivable that due to the small number of carriers identified in 
the samples resulted in low statistical power to identify additional variables as 
significant.  
 
Characterization of pneumococcal isolates revealed a high serotype and genotype 
diversity. Only one serotype (11A) was common to both areas; however, the 
genotypes and antibiotypes associated with it were distinct.  
 
This study has some limitations. Although the size of the population enrolled was 
high (c.a. 650 adults enrolled in each area) the low number of pneumococcal 
isolates identified hindered the statistical analysis. Secondly, we used culture-
based only methods to detect pneumococci, which may have resulted in a lower 
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carriage rate estimate. Although we used a selective medium to prevent 
overgrowth of undesirable bacteria, and easily identify pneumococci, we may have 
been unable to detect low-density carriers. In fact, Ogami et al. reported that real-
time PCR increased significantly detection of carriage in healthy children when 
compared to culture alone (21). The same is plausible for detection of carriage in 
adults (24). More recently, Chien et al. reported that at carriage density of ≤105 
CFU/ml detection of pneumococci by culture was significantly less sensitive than 
PCR (6). These limitations are being further explored in ongoing initiatives carried 
by this group. Our study has also some strength. It generated for the first time data 
on pneumococcal colonization patterns in the elderly in Portugal. In addition, 
pneumococcal isolates were characterized in detail and a wealth of 
epidemiological data was obtained.  
 
In conclusion, this study showed that pneumococcal colonization in the elderly in 
Portugal is low (2.2%). Colonizing isolates are very diverse in terms of genotype 
and serotype. Smoking increases the risk of being colonized with pneumococci by 
7-fold while living in an urban area seems to be a protective factor for colonization. 
This study will contribute to establish a baseline that may be used in future studies 
to monitor how novel pneumococcal vaccines impact on colonization in adults.  
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Abstract 
 
In the era of pneumococcal conjugate vaccines, surveillance of pneumococcal 
disease and carriage remains of utmost importance as important changes may 
occur in the population. To monitor these alterations reliable genotyping 
methods are required for large-scale applications. We introduced a high 
throughput multiple-locus variable number tandem repeat analysis (MLVA) and 
compared this method with pulsed-field gel electrophoresis (PFGE) and 
multilocus sequence typing (MLST). 
The MLVA described here is based on 8 BOX loci that are amplified in two 
multiplex PCRs. The labeled PCR products are sized on an automated DNA 
sequencer to accurately determine the number of tandem repeats. The 
composite of the number of repeats of the BOX loci makes up a numerical 
profile that is used for identification and clustering. In this study, MLVA was 
performed on 263 carriage isolates that were previously characterized by MLST 
and PFGE. 
MLVA, MLST and PFGE (cut-off of 80%) yielded 164, 120, and 87 types, 
respectively. The three typing methods had Simpson’s diversity indices of 
98.5% or higher. Congruence between MLST and MLVA was high. The Wallace 
of MLVA to MLST was 0.874, meaning that if two strains had the same MLVA 
type they had 88% chance of having the same MLST type. Furthermore, the 
Wallace of MLVA to clonal complex of MLST was even higher: 99.5%. For some 
isolates belonging to a single MLST clonal complex although displaying different 
serotypes, MLVA was more discriminatory generating groups according to 
serotype or serogroup.  
Overall, MLVA is a promising genotyping method that is easy to perform and a 
relatively cheap alternative to PFGE and MLST. In the companion paper 
published simultaneously in this issue we applied the MLVA to assess the 
pneumococcal population structure of isolates causing invasive disease in the 
Netherlands before the introduction of the 7-valent conjugate vaccine. 
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Introduction 
 
Streptococcus pneumoniae is an important human pathogen causing diseases 
like otitis, pneumonia, sepsis, and meningitis. The major virulence factor of the 
pneumococcus is the capsule (1, 17). Currently, over 90 different capsules have 
been identified (3, 5, 16, 31). Such high antigenic diversity has long been 
recognized and serotyping using Quellung reaction has been used for 
pneumococcal typing for several decades. In recent years, as the DNA 
sequences of the capsular biosynthetic loci became available (2, 31), alternative 
strategies for capsular typing based on genotyping methods have been 
developed (4, 22, 30) (Elberse et al. companion paper, PLoS One, this issue).  
 
For the past two decades, a number of genotyping methods aimed to assess 
the genetic diversity of pneumococcal isolates have been used. Currently, 
pulsed-field gel electrophoresis (PFGE) (15, 23) and multilocus sequence typing 
(MLST) (10) are the gold standards for genotyping of pneumococci.  
 
In PFGE, total DNA is digested with a rare cutter endonuclease (such as SmaI 
or ApaI) that yields a limited number of fragments of high molecular weight. The 
fragments are separated by a variant of gel electrophoresis in which the 
orientations of the electric field change periodically, enabling megabase size 
DNA fragments to be effectively separated by size (39). The DNA banding 
patterns are then compared between isolates and clonal relationships are 
inferred (23). Although the interpretation criteria may vary depending on the size 
of the collection and on the goal of the research being conducted, there are 
general criteria, both visual and computer-assisted that seem to work well (6, 
42). Advantages of PFGE are that it has good typeability (the percentage of 
isolates that can be assigned a type), reproducibility, and resolving power (26, 
42). In addition, the costs for materials and equipment are relatively low and 
handling of the equipment is easy. However, it is laborious and time consuming 
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and may yield ambiguous results if not performed by a well trained technician. 
PFGE is quite useful for local epidemiology and it has also been used for global 
epidemiology once standardized (27, 34). Portability between laboratories is not 
straightforward, but seems to be attainable provided protocol harmonization is 
achieved (42). 
 
Multilocus sequence typing (MLST) is a DNA sequence-based method that 
relies on PCR amplification and sequencing of internal fragments of 7 
housekeeping genes (10, 24). For allele assignment, each sequence is 
compared to all known alleles which are available at an online database 
(www.mlst.net). Different sequences (even single nucleotide difference) are 
assigned different allelic numbers. The 7 assigned allele numbers form an allelic 
profile or sequence type (ST). MLST is expensive if in-house sequencing 
facilities are not available and, therefore, many laboratories cannot afford to use 
it routinely. However, it has the advantages of being reproducible, 
unambiguous, portable allowing intra-laboratory comparisons and suited to 
create international databases. For S. pneumoniae, MLST has a good resolving 
power being useful for local and global epidemiology. Furthermore, in contrast 
to PFGE, MLST does not always require a culture and can sometimes be 
directly performed on samples containing bacterial DNA such as cerebrospinal 
fluid (9).  
 
In 1992 conserved repeated sequences, named BOX elements, were identified 
in the genome of the pneumococcus (25). The sequenced genomes of R6 and 
TIGR4 contain 115 and 127 BOX elements, respectively. BOX elements consist 
of 3 different subunits, BoxA, BoxB and BoxC. BoxB is the tandem repetitive 
unit of 45 base pairs flanked by BoxA and BoxC, although elements missing 
BoxA or missing BoxC have been described (20, 25). The function and origin of 
BOX elements are unknown; however, it is thought that they may be involved in 
regulating the expression of virulence-associated genes when they are located 
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in the promoter regions of genes (20, 25). In the years after the discovery of 
these elements a number of genotyping methods were introduced based on the 
variability of these elements. A BOX-PCR described by van Belkum and 
colleagues showed the usefulness of these repeats for genotyping (44). The 
primer of this PCR is based on the BoxA sequence and yields PCR products of 
regions present between BOX loci that are close to each other and in opposite 
direction. However, the method has the disadvantage of creating banding 
profiles, which are difficult to interpret and often lack reproducibility. A multiple-
locus variable number tandem repeat analysis (MLVA) scheme based on BOX 
typing was introduced by Koeck et al. in 2005 (21). It analyzes 16 BOX loci that 
are PCR-amplified in single PCR reactions and products are analyzed by 
agarose gel electrophoresis. A website (www.mlva.eu) providing a database in 
which profiles can be compared has been created. At the time of writing this 
manuscript the MLVA profiles of 1147 isolates had been deposited in the 
database. The many loci that are analyzed and the choice of agarose gel 
electrophoresis for sizing makes this method somewhat laborious. This MLVA 
scheme was successfully applied and compared with MLST and was shown to 
yield high congruence with MLST, but was more discriminatory than MLST (32, 
35). 
 
In this paper we describe a newly developed MLVA typing scheme for 
pneumococci based on 8 BOX elements. The 8 BOX loci are amplified in 2 
multiplex PCRs and the fluorescently labeled PCR products are sized on an 
automated sequencer yielding high throughput and unambiguous typing results. 
The generated MLVA results can be compared internationally using the newly 
available MLVA website www.MLVA.net. On the website the MLVA profiles can 
be imported to assess the MLVA type (MT). In the current study we assess the 
validity of this method by comparing MLVA with two well established genotyping 
methods: PFGE and MLST. In the companion paper published simultaneously 
in PLoS One, we applied this MLVA scheme to assess the population structure 
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of pneumococci causing invasive disease in the Netherlands before the 
introduction of the 7-valent pneumococcal conjugate vaccine. 
 
 
Materials and methods 
 
Isolate collection.  
In this study 263 pneumococcal isolates were used for the comparison of MLVA 
with PFGE and MLST. The isolates were obtained between 1996 and 2007 from 
the nasopharynx of children attending several day-care centers in the area of 
Lisbon, Portugal. The isolates were stored in glycerol broth at -80ºC and were 
characterized by antibiogram, serotyping, PFGE, and MLST under the scope of 
previous studies (28, 33, 34). Approval for the study was obtained from the 
Ministry of Education and from the directors of each day-care center. Written 
informed consent was obtained from parents or guardians of each child before 
sampling. All information was stored in an in-house developed online database. 
Overall, the collection comprised 41 serotypes, 87 PFGE types and 120 STs. 
 
Serotyping, PFGE and MLST.  
These techniques were performed as previously described. Briefly, serotyping 
was performed by the Quellung reaction (41) and/or multiplex PCR (8, 30). For 
PFGE, total DNA was extracted, restricted with SmaI, and DNA fragments were 
resolved by PFGE (34). MLST was performed using primers and conditions 
described previously (10). For allele assignment the S. pneumoniae MLST 
database available at www.mlst.net was interrogated. Sequence traces of novel 
alleles were submitted to the curator for new allele and ST assignment. 
 
Multiple-Locus Variable number tandem repeat Analysis (MLVA).  
In the genome sequence of isolate R6 (GenBank number NC_003098), one of 
the publicly available genomes, 115 BOX tandem repeats were found. Thirteen 
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randomly chosen BOX loci scattered throughout the R6 genome to be used in 
the MLVA scheme were tested on a panel of 84 isolates. Eight BOX loci were 
chosen and primers were designed targeting the flanking regions of the BoxA 
and BoxC elements (Figure 1, Table 1).  
 
Fig. 1. Schematic representation of pneumococcus R6 genome indicating the 
location of the 8 BOX loci that are used in the MLVA scheme.  
 
One primer of each primer set was fluorescently labeled with FAM, NED, VIC or 
PET. For BOX loci 4 and 6 respectively 3 and 4 primers were used to primer set 
was fluorescently labeled with FAM, NED, VIC or PET. For BOX loci 4 and 6 
respectively 3 and 4 primers were used to enhance amplification within all 
isolates. The 8 loci were amplified in 2 separate multiplex PCRs, creating 
mixtures each with 4 different fluorescent labels enabling analysis of 4 BOX loci 
in a single fragment analysis reaction (Table 1). Amplification of the loci was 
done in Applied Biosystems 9700 PCR machines. The 25 µl PCR reaction 
mixtures consisted of Qiagen multiplex PCR mix, 10 µM of each primer and 2 µl 
of 1:10 lysates diluted in sterile water. Lysates were prepared by suspending a 
loop full of pneumococci in 500 µl TE (10 mM Tris.HCl and 1 mM EDTA, pH 8) 
followed by heating for 10 minutes by 95ºC. Amplification was performed using 
the following PCR program: 15 min 95ºC, 25 cycles of 30 sec 95ºC, 1 min 54ºC 
and 1 min 72ºC followed by a 30 min incubating at 68ºC to ensure complete 
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addition of the extra 3’adenosin by the terminal transferase activity of the Taq 
polymerase. Of the PCR product mixtures, 2 µl aliquots, diluted 1:200 in water, 
were mixed with 10 µl of 1:200 diluted Genescan 1200 LIZ-marker (Applied 
Biosystems, Foster City, U.S.A.). The product was heated for 5 minutes at 95ºC 
for denaturation and sized on the AB 3730 DNA sequencer using the Fragment 
Analysis module. 
 
Determination of the number of repeats in each locus was done using the 
GeneMarker software (Softgenetics, State College, Pennsylvania, USA). For 
this purpose, fragment analysis files with the .fsa extension were imported into 
the software and the number of repeats in each locus was derived from the 
data. All alleles that yielded PCR product sizes that had not been found before, 
were analyzed by sequencing using unlabeled versions of the MLVA primers. 
This included PCR products with aberrant sizes representing loci in which 
deletions or insertions had occurred in the region flanking the BOX repeats. 
Thereafter, the loci were assigned the number of BoxB repeats present. For 
each isolate an allelic profile was generated consisting in a string of 8 integers 
reflecting the number of repeats in the 8 BOX loci. The allelic profile was 
assigned an arbitrary sequential MLVA type (MT). The correspondence between 
MT and allelic profile was deposited at the MLVA database located at 
www.mlva.net to guarantee that the same nomenclature was maintained for all 
isolates characterized by this technique regardless of its origin and study.  
 
Data Analysis. 
Analysis of PFGE patterns, MLST and MLVA numerical profiles, was performed 
using Bionumerics version 6.1 (Applied Maths, Sint-Martens-Latem, Belgium). 
PFGE patterns were clustered by UPGMA. A dendrogram was generated from a 
similarity matrix calculated using the Dice similarity coefficient with an 
optimization of 1.0% and a tolerance of 1.5%. PFGE clusters were defined as 
isolates with a similarity of 80% or higher on the dendrogram (13, 33). 
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Clustering of MLST and MLVA types were displayed in minimum spanning 
trees. In this graphic representation, the circles in the tree represent the various 
types. The size of the circle is proportional to the number of isolates with the 
same type. Lines linking two types in the tree denote single locus difference 
between those types. For assignment of MLST or MLVA clonal complex, the 
entire MLST database (available at www.mlst.net, last accessed on October 20, 
2010) or the entire in-house MLVA database (available at www.mlva.net, last 
accessed on October 20, 2010) were interrogated. MLVA complex assignment 
was based on a maximum distance of one locus between related types. The 
minimum number of MLVA types in a MLVA complex was set to 3 with a 
minimum of 9 entries per MLVA complex, resulting in on average 3 isolates 
within an MLVA type. These settings resulted in MLVA complexes that were 
strongly correlated to serotype.  
 
Statistical analysis.  
The discriminatory ability of the three typing systems - PFGE, MLST and MLVA 
- was measured using the Simpson’s index of diversity (SID) and 95% 
confidence intervals were calculated as proposed before (14, 40). The 
congruence between the typing methods was calculated using the Wallace 
coefficient (7). All calculations were done using the freely available online tool 
Comparing Partitions located at www.comparingpartitions.info (7). 
 
 
Results 
 
Multiple-locus variable number tandem repeat analysis (MLVA)  
A combination of highly diverse and less diverse BOX loci were chosen aiming 
to have a good balance between loci that would evolve faster than others. The 
13 randomly chosen BOX loci were tested on a panel of 84 isolates and 8 BOX 
loci were chosen for the MLVA scheme. The overlap in BOX loci of our MLVA 
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scheme with the MLVA scheme previously described by Koeck et al. (21) is 
provided in Table 1. In particular, BOX loci 1, 4, 12 and 13 were rather diverse 
while BOX locus 11 had less diversity. If BOX loci could not be amplified they 
were assigned allele number 99. To exclude the possibility that BOX loci could 
change by laboratory storage and repeated subculture, 4 pneumococcal isolates 
were subcultured for 29 sequential days. MLVA was performed on samples from 
days 1, 15, and 29 and no changes in the number of repeats in the 8 BOX loci 
were observed indicating that the composition of BOX loci remained stable 
under laboratory conditions (data not shown). In addition, 84 isolates were typed 
at least twice at different occasions by independent technicians and the same 
MLVA types (MT) were obtained indicating that the MLVA scheme is 
reproducible.  
 
Discriminatory power of MLVA 
The discriminatory power of MLVA was calculated by using the Simpson’s Index 
of Diversity (SID) applied to the test population. The 263 isolates were resolved 
in 164 types that contained between 1 and 14 isolates. The SID for MLVA was 
0.993, a very high value comparable to the ones obtained for PFGE (0.985) and 
MLST (0.987) (Table 2). In the Supplemental Table the MLVA, MLST and PFGE 
data is provided for all isolates that are included in this study (Table S1). The 
companion paper (Plos One, this issue) highlights its wide application to over 
1000 isolates, including 444 MLVA types. Overall, the current MLVA database 
consists of 2973 isolates, 960 MLVA types and 43 MLVA complexes. The SID 
for MLVA based on the entire database was 0.986 (95% CI, 0.985-0.988) 
(www.MLVA.net, last accessed on October 20, 2010). 
 
Comparison of MLVA with serotyping, PFGE, and MLST  
To assess the congruence between typing methods the Wallace index was 
calculated (Table 3). This coefficient indicates the probability that a pair of 
isolates which is assigned to the same type by one typing method is also typed 
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as identical by the other method. A very good directional correlation between 
MLVA and MLST results was found: the probability of two isolates having the 
same MLVA type (MT) also sharing the same MLST type (ST) was 87.4%. This 
value was even higher for predicting the MLST clonal complex: 99.5%. 
Corresponding Wallace indexes between MLVA and other typing methods were: 
82.2% for serotyping, and 46.5% for PFGE. By
isolates sharing the same ST also shared the same MT was 43.3% and sharing 
the same MLVA complex was 99.2%. Lower values were obtained for PFGE 
and serotyping. These differences can be explained by the higher discriminatory 
power of MLVA compared to the other typing methods.
 
 
Table 1. Oligonucleotide primer sequences used in 
1
 Primer is fluorescently labeled. F: FAM; N: NED; V: VIC; P: PET.
2
 Additional primer because of polymorphism in primer sites
 
 contrast, the chance that two 
  
S. pneumoniae MLVA scheme. 
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Relatedness of isolates with similar types when assessed by MLVA or 
MLST 
Although there was considerable concordance between MLST and MLVA, some 
of the isolates that were grouped by MLST could be further distinguished by 
MLVA. In Figure 1A a minimum spanning tree is depicted based on the MLST 
results for the 263 isolates of the test collection. Fifty-six clonal complexes (CC), 
and 13 singletons were detected and the 7 largest CCs were chosen for further 
comparisons and are highlighted in color. To visualize the relationship between 
MLST and MLVA, the same color legend was applied to the minimum spanning 
tree based on MLVA (Fig. 1B). To create this minimum spanning tree, the 
entries in the entire MLVA database (n=2973) were used. Subsequently, a 
subnetwork was generated displaying the branches and complexes of the 
complete tree but only the nodes representing the isolates used in this study. 
 
Table 2. Simpson’s Index of Diversity of the different typing methods  
Typing method SID1 [95% CI] No. of types 
Serotyping 0.937 [0.926-0.948] 41 
PFGE  0.985 [0.983-0.988] 87 
MLST 0.987 [0.981-0.992] 120 
MLST_CC2 0.963 [0.955-0.971] 56 
MLVA 0.993 [0.991-0.996] 164 
MLVA_MC3 0.935 [0.918-0.953] 25 
1
 SID, Simpson’s Index of Diversity; 95% CI, 95% confidence interval 
2 CC, clonal complex 
3 MC, MLVA complex 
 
MLST CC28 included isolates with serotype 6A and 6C which were also closely 
related when characterized by MLVA. Similar results were obtained for MLST 
CC1, CC7 and CC32. CC16 included isolates of serotypes 6A, 6C, and 10A; 
isolates of serotype 10A were clearly separated by MLVA from the serotype 6A 
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and 6C isolates. CC2 consisted of serotype 6A, 6B, 6C, 15B and 23F isolates. 
The serotype 6A, 6B and 6C isolates were separated in 2 distinct groups when 
they were characterized by MLVA. The 15B and 23F isolates were clearly 
distinct and yielded completely different MTs. This was an example were MLVA 
distinguished isolates with different serotypes that were grouped within a single 
CC. The same could be observed for MLST CC4 that comprised serotypes 23A, 
23B and 23F that were dispersed into 2 groups using the MLVA.  
 
In this test collection there were 9 instances where isolates were characterized 
by MLST as two different types, whereas by MLVA these isolates yielded the 
same type. These isolates were all single locus variants, except for a single 
isolate.  
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Table 3. Congruence between typing methods expressed by Wallace coefficients 
 
Wallace coefficient [95% CI] 1 
Typing method Serotype PFGE MLST MLST_CC2 MLVA MLVA_MC3 
Serotype  0.091 [0.064-0.118] 0.187 [0.132-0.242] 0.343 [0.279-0.407] 0.087 [0.053-0.122] 0.631 [0.553-0.710] 
PFGE 0.386 [0.329-0.442]  0.325 [0.273-0.376] 0.550 [0.493-0.607] 0.209 [0.157-0.261] 0.718 [0.649-0.786] 
MLST 0.875 [0.848-0.902] 0.358 [0.276-0.439]  1.000 [1.000-1.000] 0.433 [0.316-0.550] 0.992 [0.983-1.001] 
MLST_CC2 0.575 [0.526-0.623] 0.232 [0.180-0.284] 0.419 [0.356-0.481]  0.202 [0.140-0.263] 0.881 [0.849-0.912] 
MLVA 0.822 [0.779-0.865] 0.465 [0.396-0.535] 0.874 [0.825-0.923] 0.995 [0.991-1.000]  1.000 [1.000-1.000] 
MLVA_MC3 0.769 [0.717-0.822] 0.295 [0.224-0.366] 0.582 [0.486-0.679] 0.998 [0.997-1.000] 0.295 [0.199-0.391]  
1 95% CI, 95% confidence interval; 2 CC, clonal complex; 3 MC, MLVA complex 
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Fig. 2 (left page). High congruence between MLVA and MLST. Minimum 
spanning tree of the results obtained by MLST (A) and MLVA (B) for the 263 
isolates of the test collection. Each circle indicates a genotype. The size of the 
circle is proportional to the number of isolates with the same type. Lines linking 
two types denote a single locus difference between those types. In Figure 1A 
the MLST complexes are indicated by halos. Seven MLST complexes are 
discussed in the manuscript and these are colored and named according to the 
nomenclature of S. pneumoniae MLST database (www.mlst.net, last accessed 
on October 20, 2010). The white nodes represent the isolates within this test 
collection that are not discussed. The same colors were applied to the minimum 
spanning tree based on MLVA in Figure 1B. This minimum spanning tree is 
based on the entire MLVA database (last accessed on October 20, 2010), and 
only the branches are made visible. The MLVA types of the 263 isolates used in 
this study were depicted as circles. The halos indicate the MLVA complexes.  
 
M
LV
A 
fo
r 
St
re
pt
o
co
cc
u
s 
pn
e
u
m
on
ia
e
 
150 
 
Discussion 
 
In recent years, typing schemes based on MLVA have been designed and 
implemented for a number of micro-organisms of public health importance, 
including Bacillus anthracis, Staphylococcus aureus, Enteroccus faecium, 
Haemoplhilus influenza, Bordetella pertussis and many others (11, 12, 18, 19, 
29, 36-38, 43). MLVA-based typing strategies have several appealing 
characteristics that match the convenience criteria desirable for typing methods 
(45). For example, once implemented MLVA requires minimal technical 
expertise and typing results can be obtained in a few hours providing a 
sequencing facility is readily available. The equipment needed is the same as 
for MLST, i.e., a thermocycler and a DNA sequencer, equipment that many 
laboratories performing typing have already access to. It is relatively low cost 
(cheaper than MLST) and the data are amenable to automatic analysis by 
computer software (as in MLST). Furthermore, the results are unambiguous 
numerical profiles, portable, and thus suitable for intra-laboratory comparisons. 
In addition, PFGE can only be performed on bacterial cultures while MLST can 
be performed on clinical samples containing bacterial DNA such as 
cerebrospinal fluid (9). The MLVA has the same potential as MLST, although 
this has not been described in detail yet.  
 
In this study we assessed the validity of a MLVA strategy developed for 
Streptococcus pneumoniae using as a test collection over 263 pneumococcal 
isolates previously characterized by the three gold-standard pneumococcal 
typing methods: serotyping, PFGE, and MLST. The scheme explored 
polymorphisms scattered throughout the genome of R6 focusing in eight BOX 
loci for size estimation. The amplification of the 8 loci was combined in two 
multiplex PCR reactions. Fragment sizing was performed automatically on a 
DNA sequencer, resulting in a fast, easy and accurate interpretation of results.  
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The MLVA for the pneumococcus was first described by Koeck et al. (21). In 
that MLVA scheme, 16 BOX loci were used and analyzed by agarose gel 
electrophoresis. Remarkably, 7 of the 8 BOX loci used in our MLVA scheme 
overlap with loci included in the previously published MLVA. We started the 
selection of the loci for our MLVA already in 2005, before the publication of the 
MLVA by Koeck et al. and thus the selection was performed independently. 
Therefore, the overlap is coincidental, but suggests the proper choice of a 
combination of more and less diverse loci in both MLVA schemes was made. 
The main advantage of our MLVA is the high throughput that is facilitated by the 
use of two multiplex assays instead of 16 separate reactions as done by Koeck 
et al. and the use of capillary electrophoresis for sizing. Furthermore, the 
electronic data management that we propose makes it easier to analyze the 
data than images of bands obtained by agarose gel electrophoresis. We 
restricted our MLVA to 8 VNTR loci to limit the amount of work required to type 
an isolate. Our results show that this scheme yields a high resolution. The 
resolution will probably be even higher if more loci were used like in Koeck’s 
MLVA scheme. However, this will depend on the questions that need to be 
answered. For our studies MLVA should be utilized to determine the genetic 
background of isolates and relate this to changes in other properties such as 
capsular composition. In that case MLVA based on 8 loci seems to suffice. Of 
note, both MLVA schemes showed a high congruence with MLST (32, 35).  
 
Although the test collection included only carriage isolates, we do not consider it 
a limitation to the validation study for the following reasons: (i) it is a very 
diverse collection that includes epidemiologically unrelated, as well as closely-
related isolates; (ii) it is well known that there are substantial overlaps among 
isolates being carried and causing disease at a given time and geographic 
location although the relative frequency in each group may vary significantly 
(34); (iii) this MLVA scheme has in the mean time been successfully applied to a 
collection of over 1000 invasive disease isolates from all over the Netherlands 
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(Elberse et al. companion manuscript, PLoS One, this issue). In addition, in a 
manuscript in preparation we will use the MLVA to assess temporal changes 
and vaccine related changes in the genetic background of the pneumococcus.  
 
We found that the MLVA scheme described here met all the performance 
criteria needed for a good typing method (45): it was stable, typed 100% of the 
isolates, was reproducible and had a high discriminatory power. Of interest, the 
congruence between MLVA and MLST was very good suggesting it can be 
routinely used as an alternative technique to MLST. Furthermore, MLVA was 
able to discriminate between putative capsular variants sharing the same MLST 
in a number of occasions suggesting an enhanced epidemiological usefulness. 
To make this MLVA scheme easily available to the typing community, an 
electronic pneumococcal MLVA database located at www.MLVA.net has been 
created. This application contains the detailed protocol and materials needed for 
implementation of the MLVA scheme, contact information to obtain control 
samples, an application for MLVA assignment, and a database for international 
deposition of MLVA types.  
 
In summary, the MLVA scheme for pneumococci proposed in this study has the 
convenience and performance criteria needed for a good typing method. It has 
the advantages of being portable as MLST but is faster and has lower costs. 
The high congruence between MLVA and MLST suggests it can be applied as a 
general methodology and, if needed, MLST may be performed on selected 
isolates from clusters sharing related MT. In the era of pneumococcal conjugate 
vaccines, close surveillance of pneumococcal populations is of crucial 
importance; this MLVA scheme represents a high-throughput typing technique 
which combines easiness, speed, low cost, and portability and therefore can be 
a rather useful tool to achieve such goal. 
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Concluding Remarks  
Since 1996, our research group has been monitoring the pneumococcal 
population that colonizes children attending day care centers in the Lisbon area, 
Portugal. Our studies have been providing valuable information on the 
pneumococcal population, the role of DCC as epidemiological units and the 
importance of the nasopharynx of children as a reservoir for dissemination into 
the community of epidemic clones frequently associated with disease. 
 
The introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 
2001 in Portugal led to a massive shift in pneumococcal nasopharyngeal flora in 
children attending day care centers in the Lisbon area (22, 23). In those studies 
it was observed that, despite the dramatic decrease of PCV7 serotypes among 
carriers, the pneumococcal carriage and the antimicrobial resistance rates 
remained essentially unchanged in the years following the introduction of PCV7 
in Portugal. 
 
To explore to which extent this scenario was mimicked in other regions of 
Portugal we performed the studies described in Chapters III and IV in two other 
regions: Coimbra, a city in the central region, and Montemor-o-Novo, a rural 
area in the south.  
 
In the study conducted in Coimbra, described in Chapter III, nasopharyngeal 
swabs were taken from children attending day care centers. Around 65% of the 
children were age-appropriately vaccinated with PCV7 and similar rates of 
pneumococcal colonization (c.a. 60%), antimicrobial resistance patterns, and 
genotypes were found when compared to previous studies conducted in the 
Lisbon area.  
 
In the study, described in Chapter IV, we compared the patterns of 
pneumococcal colonization among young children attending day care centers in 
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the rural area of Montemor-o-Novo with those of young children attending day-
care in the urban area of Lisbon. In this study around 70% of the children, in 
both areas, were age-appropriately vaccinated. Although similar rates of 
colonization were found in the two areas (c.a. 60%), the rates of antimicrobial 
consumption and pneumococcal antimicrobial resistance were significantly 
higher in the urban area.  
 
A multivariable logistic regression helped us to identify the factors which 
contributed for these differences between the two areas and we found that 
antibiotic consumption in the month preceding sampling, attending day care in 
the urban area, and being colonized with serotype 19A and non-typeable strains 
increased the probability of being colonized with pneumococcal antimicrobial 
resistant strains.  
 
With these studies we were able to conclude that: (i) although the 
pneumococcal vaccines are not introduced in the Nacional Vaccination Plan of 
Portugal, at least in these three regions, at the time of these studies, the use of 
PCV7 was high and comparable, (ii) the rates of pneumococcal colonization 
were similar in these regions, and (iii) antibiotic consumption remains the main 
cause for maintenance of antimicrobial resistance among circulating 
pneumococci.  
 
Pneumococcal colonization is required for the occurrence of pneumococcal 
disease and also for transmission. For this reason it is essential to study 
colonization in the two age groups where the rates of pneumococcal infection 
are higher: children under six years old and adults with more than 60 years of 
age. To gain insights of pneumococcal carriage patterns in adults living in 
Portugal, a study was started in 2010 and the first results are described in 
Chapter V. Low rates of colonization (2.2%) were found and these are  in 
agreement with those reported in other countries (1, 10, 16, 20). Taking into 
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account the low number of pneumococcal carriers, we were not able to reach 
robust conclusions in this study regarding factors associated with carriage in the 
elderly. However, smoking increased in seven fold the risk of being colonized by 
pneumococci and living in a rural area seems to increase the risk of 
pneumococcal colonization.  
 
In 2007, Park and co-authors described a new pneumococcal serotype, 6C (17), 
that was previously indistinguishable from serotype 6A by the Quellung reaction. 
More recently, other serotypes have been discovered: 6D (3), 11E (previously 
indistinguishable from serotype 11A) (4), and serogroup 20 was divided in 20A 
and 20B (5). All these discoveries and the exact determination of the serotypes 
are particularly important, in the era of conjugate pneumococcal vaccines, to 
better understand vaccine impact and control for the possibility of cross-reaction 
with non-vaccine types. Serotype 6C aroused a special interest since PCV7 
targets serotype 6B, and it is presumed to induce cross-protection against 
serotype 6A, but not against 6C (17).  
 
Additionally at the time of the study described in Chapter II, few studies about 
the epidemiology of this serotype had been published. Nevertheless, one study 
from South Africa had reported a higher propensity of this serotype to cause 
meningitis, in HIV+ adults, than serotype 6A or 6B strains (9). A study from CDC 
in the USA reported a significant increased of the rate of invasive disease 
caused by serotype 6C between 1999 and 2006 (7). Another study from Ohio 
also reported increase of serotype 6C after 2001 (14).  
 
In the retrospective study described in Chapter II, a collection of strains of 
serogroup 6, recovered from young healthy children, between 1996 and 2007 
were serotyped by PCR using the specific primers for serotype 6C described by 
Park et al. (17). Additionally, the serotype 6C strains were characterized by 
PFGE and MLST. It was observed that this serotype had been circulating in 
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Portugal at least since 1996. This serotype was genetically diverse, and often 
antibiotic resistant.  
 
Several studies about serotype 6C have been published in more recent years, 
from different geographic areas. Some have documented an increase of this 
serotype in carriage and in disease after PCV7 vaccination (11, 13, 21, 25). In 
other studies, conducted before the introduction of PCV7, as in Brazil and Israel, 
serotype 6C has also been found in circulation in colonization and disease (6, 
18). PCV13 can potentially impact on this serotype, since this vaccine includes 
serotype 6A and may provide some cross-protection against serotype 6C (8).  
 
With the introduction of pneumococcal vaccines, surveillance of pneumococcal 
disease and carriage remains of extreme importance since changes are 
expected to occur in the pneumococcal population. To monitor these alterations 
reliable genotyping methods are required for large-scale applications. In 
Chapter VI a new scheme of multiple-locus variable number tandem repeat 
analysis (MLVA) for Streptococcus pneumoniae is proposed. This technique 
was compared with the two gold standard methodologies for pneumococcal 
typing, MLST and PFGE. Since the MLVA methodology proposed is a high-
throughput typing technique that can be easily done, in short time, and with low 
cost (as long as there is access to a sequencer), and has the advantages of 
portability and access to a web-based database (as MLST), MLVA can be a 
rather useful tool to achieve such goal. 
 
Overall, the studies performed in this thesis have contributed to a better 
knowledge on pneumococcal colonization in Portugal in two age groups, 
children and the elderly. In summary the main conclusions were: 
i) the recently described serotype 6C is frequently carried by healthy young 
children in Portugal, is genetically diverse, and has been circulating in 
our country at least since 1996;  
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ii) the patterns of pneumococcal colonization among healthy children living 
in Coimbra are similar to those living in the Lisbon area; 
iii) antibiotic consumption remains a main cause for the maintenance of 
antimicrobial resistance, in the era of widespread use of pneumococcal 
conjugate vaccines;  
iv) the rates of pneumococcal colonization in the elderly are low and the 
serotype and genotype diversity are high; 
v) MLVA is a promising genotyping method to characterize pneumococci.  
 
Future perspectives 
Further studies would be important in the context of the work presented in this 
thesis and should involve: 
I) characterization of serotype 6C after 2007, mainly observing the 
possible cross-protective effect of PCV13 in this serotype; 
II) continuous surveillance on the impact of novel pneumococcal 
conjugate vaccines (PCV10 and PCV13), not only in pneumococcal 
serotypes but also in the levels of antimicrobial resistance among 
pneumococcal colonizing healthy children; 
III) continuous surveillance studies on colonization in the elderly in order 
to increase the data that could help us to take more precise 
conclusions, mainly in risk factors associated with pneumococcal 
carriage, the diversity of serotypes and genotypes. In this latter study 
the use of real time PCR would be a good tool in order to estimate 
the real rates of pneumococcal colonization; 
IV) widespread use of MLVA by other laboratories in other countries in 
order to use this tool linked to its online database to rapidly, and 
cost-effectively characterize pneumococci by being able to easily 
make inter-laboratory comparison. 
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Additionally, it would be important to design a good follow-up study that could 
closely measure the variations of the nasopharyngeal flora over time. It would 
also be interesting to understand the relationships of the entire microbiome in 
the nasopharynx and verity if “virus colonization” exists as it has been proposed 
by some authors (19, 24, 26, 27). This notion could be important to complement 
the idea of a recent paper published by Launes et al. (15), which mentions that 
viruses may facilitate the invasiveness of less invasive pneumococcal 
serotypes.  
 
Other important aspect, which was mentioned in the introduction, are the rates 
of pneumococcal vaccine coverage and its impact in on pneumococcal 
epidemiology. In Portugal pneumococcal vaccines are not part of the National 
Vaccination plan but in 2010, about 70% of our population in pre-school age 
was age-appropriately vaccinated. Taking into account the serious economic 
situation of the country, probably the vaccination rate will decrease and this 
might change the epidemiology of pneumococci in Portugal. I wonder what will 
happen. Can the PCV7 serotypes become more prevalent again? Which 
consequences might this have on the levels of antimicrobial resistance? And in 
disease, what will happen? The latest reports on IPD in Portugal indicate that 
serotypes 1, 7F and 19A are the most prevalent in IPD in our country (2, 12). 
Considering that these serotypes are included in PCV13, which is currently on 
the market, a decrease in the vaccination uptake might counteract the 
decreasing tendency in the proportion of IPD in Portugal. 
 
Finally, the studies described are an added value to our knowledge on 
pneumococcal epidemiology in the nasopharynx, in the era of pneumococcal 
conjugate vaccines. We described for the first time the pneumococcal 
colonization patterns in adults aged over 60 years, in Portugal. This can 
constitute a baseline to monitor the changes that might occur with the 
introduction of PCV13 for adults. Moreover, the study of serotype 6C was one of 
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the first to be published after its discovery, reporting important information 
regarding this serotype. As a final point, in this thesis we validated the 
application of a promising genotyping method to pneumococci, which, due to its 
characteristics, might be a good candidate as a gold-standard genotyping 
method. 
 
From my point of view, epidemiological surveillance studies in carriage as well 
as in disease will continue to be helpful to show more pieces of the enigmatic 
pneumococcus that “everyday” lifts the veil and lets us learn a little more about 
itself. 
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